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ABSTRACT
The ABC transporter P-glycoprotein (Pgp) and membrane permeability are
determinant factors for absorption and disposition of xenobiotics. These studies
investigated the effects of potential modulators of Pgp and/or membrane function on the
disposition,

bioavailability

and

bioaccumulation

of

environmentally

relevant

pharmaceuticals, tetracycline and ivermectin, and the carcinogen benzo[a]pyrene in
catfish. The pesticide dieldrin and surfactant linear alkylbenzene sulfonate (LAS) were
selected as mixture components thought to have potential interactions with these
determinants of disposition. Initial in situ experiments demonstrated dieldrin and
tetracycline both significantly inhibited biliary excretion of Pgp prototypic substrate
Rhodamine-123 in isolated perfused livers. Further, dieldrin (20µM) reduced movement
of 3H-tetracycline (8.8nM) into bile (55%) to a greater extent than Pgp prototypic
competitive inhibitor verapamil. In contrast to inhibitory effects in situ, a 4-week dietary
dieldrin preexposure (0.1mg/day/kg body weight) increased plasma clearance (17%) and
reduced tissue concentrations of 3H-tetracycline equivalents (parent and metabolites) for
a single intra-aortic administration of 3H-tetracycline (8.31µg/kg body weight) in catfish.
A 23% increase in the immunoreactive Pgp level in the hepatic membranes following
chronic dietary dieldrin exposure was correlated with in vivo changes in disposition.
Additional in situ studies demonstrated LAS treatments (1, 5, and 20µM) reduced
movement of Rhodamine-123 (1µM) into bile in isolated perfused livers (18.6, 38.1 and
66.7%, respectively). Fluorescent anisotropy measurements of the corresponding hepatic
membranes showed a 29.7% decrease (increase in membrane fluidity) at the 1µM LAS
concentration, with little additional change evident at higher concentrations. In sequential
in vivo experiments, following six daily diet administrations of 3H-ivermectin (10
viii

µg/day/kg body weight) or 3H-benzo[a]pyrene (40 µg/day/kg body weight) starting on
day 7 during a twelve-day waterborne LAS exposure (0, 100 and 300µg/l), 3H-ivermectin
and 3H-benzo[a]pyrene equivalent remaining in catfish and their blood and tissue
concentrations increased in a dose-dependent fashion with increasing LAS concentrations.
The first study indicates dieldrin inhibited Pgp transport at the high concentration with
the inductive effect upon Pgp expression predominating at the low concentration
exposures in vivo. Findings of the second study suggest that LAS at environmental
concentrations altered membrane permeability and/or transporter function so to increase
bioaccumulation of other xenobiotics from the diet.

ix

INTRODUCTION
A wide range of anthropogenic contaminants are found in the aquatic
environment. Fish living in those environments may be exposed to various contaminants
as well as pharmaceutical drugs entering the water from domestic, agricultural and
aquaculture applications. Many factors are known to influence bioavailability and
bioaccumulation of these chemicals in fish (Leblanc, 1995; Ivanciuc et al., 2006).
Membrane permeability is generally considered as a key determinant in the extent of
absorption, distribution and elimination of chemicals in the body. Exposure concentration
and duration, compound lipophilicity and the susceptibility of the chemical to
biotransformation also play a role in dictating contaminant body burdens. Recently,
studies in mammals suggest that Phase III transport processes by ABC (ATP binding
cassette) transporters such as P-glycoprotein (Pgp) may have a significant effect on
xenobiotic bioavailability and bioaccumulation (Kurata et al ., 2002; Liu and Hu, 2000;
Fromm, 2000; Shitara, 2006).
Membrane permeability may affect the transfer of the xenobiotics in the body in
various ways (Malkia et al., 2004). The gastrointestinal tract provides an efficient barrier
to the permeability of some xenobiotics, while chemicals are readily permeable as a
function of physicochemical characteristics of the compound and the membrane (Smith et
al., 1996; Lin, 2003). In addition, the gastrointestinal tract is lined with transporters
which “pump” absorbed xenobiotics back into the intestinal lumen. Such an action
reduces systemic bioavailability in a compound specific manner. Increases in
gastrointestinal tract membrane permeability may facilitate xenobiotic uptake from the
diet as a means to circumvent the transport barrier function. In the liver, the compound
enters into the hepatocyte from the blood and is actively transported from the hepatocyte
1

across the canalicular membrane into bile for clearance of the compound. In this case,
increased membrane permeability in the liver short-circuits active transport and clearance
by allowing the compound to move from the higher concentration of the bile back into
the hepatocyte. This action promotes compound retention in the body.
The transfer of xenobiotics in the body is generally controlled by their
permeability across tissue membranes. However, increased diffusion across the biological
membranes is not always predicative increased permeability due to the contribution of
active efflux transporters (Ayrton and Morgan, 2001). Pgp, an ATP-dependent
transmembrane transporter, is best known for efflux movement of various therapeutic
agents actively out of the cell. First observed and overexpressed in multidrug resistance
(MDR) tumor cells, Pgp has been found in normal mammalian tissues, especially in the
luminal face of intestine, the biliary canalicular membrane of hepatocytes, the apical
surface of epithelial cells of kidney and as part of the blood-brain barrier (Wacher et al.,
2001; Frohlich et al., 2004). Owing to its location in organs of absorption, the blood-brain
interface and organs of elimination, the functionality of the Pgp transporter in
conjunction with membrane permeability may be a significant factor in compound
absorption, distribution and elimination.
A Pgp-mediated multixenobiotic resistance (MXR) mechanism has also been
associated with modulation of xenobiotic bioavailability and bioaccumulation in aquatic
organisms (Kurelec, 1995). Fish have been shown to have Pgp “like” protein which
displays a high degree of sequence homology (Chan et al., 1992), a similar tissue
distribution pattern (Kleinow et al., 2000), and transport function consistent with those
known in mammals (Schramm et al., 1995; Smital et al., 2004). One of the most
remarkable features for the Pgp transporter in both mammals and fish is its broad
2

substrate specificity. Substrates which have been identified include various therapeutic
agents, certain food constituents (Balayssac et al., 2005), hormones (Leslie et al., 2005),
as well as a number of contaminants (Galgani et al., 1996; Toomey et al., 1996; Bard,
2000; Leslie et al., 2005). With the exception of moderate hydrophobicity or
amphiphilicity, few common chemical characteristics have been identified among Pgp
substrates (Gottesman and Pastan, 1993; Kusuhara et al., 1998).
A variety of environmental xenobiotics have been shown to inhibit Pgp transport
activity either as competitive or noncompetitive inhibitors. Four hydrophobic pesticides
including dacthal, chlorbenside, pentachlorophenol, and sulfallate, for example, have
been shown to reduce Pgp-mediated Rho-123 efflux from special gill cells in the mussel
Mytilus galloprovincialis (Cornwall et al., 1995; Galgani et al., 1996). Similarly, in
mussels (M. galloprovincialis), exposure to Diesel-2 oil increased accumulation of the
Pgp substrate, 3H-vincristine (VCR) threefold (Kurelec, 1995). On the opposite extreme,
induction of Pgp has also been observed following exposure to environmental
contaminants. Polycyclic aromatic hydrocarbons, including benzo[a]pyrene (BaP) and 3methylcholanthrene

(3-MC)

(Fardel

et

al.,

1996),

and

the

carcinogen

2-

acetylaminofluorene (AAF) (Chieli et al., 1995; Tateishi et al., 1999) increased
expression of Pgp in rat hepatocytes. As a consequence, absorption and disposition of
Pgp mediated xenobiotics may be altered by a variety of compounds in environmental
mixtures, which inhibit or induce Pgp.
In the aquatic environment, certain contaminants may have the potential to
interact with the lipid membrane and/or Pgp transporter, leading to altered bioavailability
and bioaccumulation of other pollutants and drugs from the environment. In the present
studies, the pesticide dieldrin and surfactant linear alkylbenzene sulfonate (LAS) were
3

selected as model contaminants to investigate their effects on xenobiotic bioavailability
and bioaccumulation because of their possible interactions with the lipid membrane
and/or Pgp transporter, environmental relevance, and their frequent exposure to fish and
other wildlife.
Dieldrin is an extremely persistent and toxic organochlorine pesticide, which has
been shown to readily bioaccumulate in fish, wildlife and humans (ASTDR 2002). It is
found in all environmental media. Fish are at high risk of being exposed to dieldrin
through the food chain and direct contact (Jorgenson, 2001). Studies have shown that
dieldrin is a potent activator of human pregnane X receptor (PXR) (Coumoul et al., 2002;
Lemaire et al., 2004), which is the master regulator for Pgp and CYP 3A4 expression
(Veau et al., 2002; Matheny et al., 2004). In addition, chronic dieldrin treatment altered
hepatic disposition of

14

C-dieldrin and 3H-7, 12-dimethylbenz[a]anthracene (DMBA)

(Gilroy et al., 1993 and 1996), and stimulated biliary excretion of 3H-DMBA and

14

C-

BaP in rainbow trout (Donohoe et al., 1998; Barnhill et al., 2003). These results were
evident without induction of xenobiotic metabolizing enzymes, suggesting that
transporter interactions may be operative with these findings.
Surfactants, common environmental pollutants and mixture components in
aquatic systems (Ahel et al., 1993; Todorov et al., 2002), generally exhibit a low order of
direct toxicity to aquatic organisms, however, several early studies suggest that
surfactants may have an effect upon the bioavailability and disposition of
environmentally relevant compounds in fish (Mann, 1962; Solon, et al., 1969; Pärt et al.,
1985). Contemporary studies on the involvement of ABC transporters in cancer
multidrug resistance have shown that surfactants are able to inhibit Pgp’s contribution to
this phenomenon (Kabanov et al., 2002). Recently, surfactants used in drug formulations
4

have been shown to increase intestinal absorption and decreased the elimination of drugs
through alteration of membrane permeability (Drori et al., 1995; Hendrich and Michalak,
2003) and/or modulation of ABC transporters (Woodcock et al., 1992; Nerurkar et al.,
1996; Regev et al., 1999; Alqawi and Georges, 2003). Therefore, through these actions, it
is of interest to determine if surfactants at environmentally relevant concentrations may
influence bioavailability or bioaccumulation of other more hazardous xenobiotics present
in environmental mixtures.
The overall objective of these studies was to investigate the influence of the
pesticide, dieldrin, and the widely used surfactant, linear alkylbenzene sulfonate (LAS)
on xenobiotic bioavailability and bioaccumulation through the alteration of ABC
transporters and/or membrane permeability. The first hypothesis examined in the in situ
isolated perfused liver and in vivo in the catfish if the disposition and pharmacokinetics of
the drug tetracycline may be altered by dieldrin through Pgp inhibition or induction.
Tetracycline was chosen for its structural similarity to Rho-123, the prototypic Pgp
substrate, its minimal metabolism in the body (Aronson, 1980) and its widespread use in
humans and animals. The second hypothesis examined if C18 LAS at environmentally
relevant concentrations may alter membrane permeability and/or the efflux activity of
Pgp in the bile canniculi of the catfish liver and influence the in vivo dietary
bioaccumulation of the pharmaceutical drug ivermectin (IVM) and pro-carcinogen
benzo(a)pyrene (BaP) in catfish. The widely used veterinary pharmaceutical ivermectin
and the PAH and environmental contaminant benzo[a]pyrene (BaP) were selected as
model compounds based on their possible involvement with ABC transporters,
environmental relevance and their otherwise limited bioaccumulation.

5

In order to address the above questions, the specific objectives of these studies are
as follows:
1. To characterize the effects of dieldrin and tetracycline on Pgp transport activity using
isolated perfused liver preparations.
2. To evaluate the effect of dieldrin on biliary excretion of 3H-tetracycline in the in situ
isolated perfused livers.
3. To examine the effects of chronic dieldrin pretreatment on the in vivo
pharmacokinetics and disposition of 3H-tetracycline in catfish.
4. To evaluate Pgp expression in association with alterations of pharmacokinetics and
disposition of 3H-tetracycline in dieldrin pretreated catfish.
5. To investigate the influence of C18 LAS at environmentally relevant concentrations on
movement of the Pgp prototypic substrate Rhodamine-123 into bile in the in situ isolated
perfused livers.
6. To assess fluidity changes in the corresponding hepatic membranes and their
relationship with inhibitory effects of LAS on movement of Rhodamine-123 into bile in
the in situ isolated perfused livers.
7. To investigate the effects of the C18 LAS surfactant at environmentally relevant levels
on the in vivo bioavailability and bioaccumulation of 3H-IVM and 3H-BaP in catfish.
The first chapter of this dissertation presents a literature review of the discovery,
structure, action mechanisms and substrate specificity of ABC transporters Pgp and Mrp,
a discussion of possible mechanisms that may modulate transport function or induce the
overexpression of these ABC transporters, membrane permeability as well as relevant
xenobiotics in these studies. The second chapter examines effects of dieldrin upon
pharmacokinetics and disposition of tetracycline through interactions with Pgp in in situ
6

isolated perfused livers and in vivo catfish. The third chapter investigates the effect of
C18 LAS on the function of Pgp and membrane permeability in the isolated perfused
livers and the influence of LAS at environmentally relevant concentrations on the in vivo
bioaccumulation and bioavailability of 3H-IVM and 3H-BaP. The fourth chapter presents
an overall summary and general conclusions.
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CHAPTER 1: LITERATURE REVIEW
ABC TRANSPORTERS: PGP AND MRP
Background: The Multidrug Resistance (MDR)
The phenomenon of multidrug resistance (MDR) was first discovered in the early
1970s. After a course of chemotherapy, tumor cells were found to exhibit reduced
sensitivity to the administered drugs and a variety of other compounds. These crossresistant agents appeared to have no common chemical structure, pharmacological
function or pathway of biotransformation (Kessel et al., 1968; Biedler et al., 1975).
Subsequent studies have shown that this form of resistance can be attributed to an active,
ATP-dependent efflux of various agents from inside the cell across the plasma membrane
to the outside (Higgins et al., 1998; Dean et al., 2001). P-glycoprotein (Pgp) was the first
and best studied membrane transporter involved in this resistance phenotype in cancer
cells (Juliano and Ling, 1976). The second major protein responsible for MDR is the
multidrug resistance-related protein (Mrp). Pgp and Mrp both belong to the ABC (ATP
binding cassette) protein superfamily, containing conserved sequences for ATP binding
and hydrolysis (Doige and Ames, 1993; Higgins, 1992). Therefore, these proteins have
been proposed to actively transport chemical agents across the plasma membrane using
the energy released by ATP binding and hydrolysis (Doige and Ames, 1993).
Although, the physiological role of Pgp and Mrp is unknown, it has been
suggested that they are associated with an ancient-type cellular immune apparatus,
providing resistance to endogenous and exogenous toxicants (Sarkadi et al., 1996). In
addition to tumor cells, these proteins are located in intestine, liver, kidney, adrenal
gland, placenta, testes and blood-brain barrier (Cordon-Cardo et al., 1989, Thiebaut et al.,
1987). The anatomical localization of Pgp and Mrp suggests that these MDR transporters
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may play an important role in absorption, distribution, and excretion of endogenous and
exogenous chemicals (Lin, 2003).
MDR in Aquatic Organisms
ABC transporters are members of a superfamily of transmembrane (TM) proteins.
This family is one of the largest and most ancient protein families with representatives in
all living organisms from prokaryotes to mammals (Higgins and Gottesman, 1992;
Ambudkar et al., 1999). Highly conserved MDR genes (encode Pgp) or Pgp-like proteins
have been observed in different aquatic organisms including sponges, oysters, clams,
worms and fish (Toomey and Epel, 1993; Waldmann et al., 1995; Minier et al., 1996;
Kurelec et al., 1992; Kleinow et al., 2000). Studies with fish have shown a high sequence
homology (Chan et al., 1992), a similar tissue distribution pattern (Kleinow et al., 2000),
and transport function consistent with that demonstrated in mammals (Schramm et al.,
1995). Mrp-related genes or proteins have also been found in Atlantic killifish (Fundulus
heteroclitus), dogfish shark (Squalus acanthias) and red mullet (Mullus barbatus) (Miller
et al., 1998; Sauerborn et al., 2004; Miller, 2003).
The MDR-like phenomenon occurring in aquatic organisms is referred to as
multixenobiotic resistance (MXR). Pgp and Mrp in aquatic organisms may constitute a
“first line of defense” to prevent absorption and facilitate elimination of endogenous and
exogenous toxicants (Epel, 1998; Kurelec, 1995). This role in chemical defense may
contribute to the observation that many aquatic species are able to survive and reproduce
successfully in highly contaminated environments with multiple anthropogenic pollutants
and natural toxins (Smital et al., 2004).
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Structure and Mechanisms of Action
The classification of ABC proteins is based on the sequence and organization of
their conserved nucleotide binding domain(s) as well as the homology in the gene
structure (Leslie et al., 2005). Typical ABC transporters contain a four-domain structure
with two conserved nucleotide binding domains (NBDs) and two membrane spanning
domains (MSDs) each consisting of six membrane spanning helices. In this structure,
each MSD is followed by a NBD (MSD-NBD-MSD-NBD) (Fig. 1. B) (Loo and Clarke,
1999). The 170 kDa Pgp (encoded by ABCB1 or MDR gene) is a typical ABC protein,
whereas the 190 kDa Mrp1 and Mrp2 (encoded by ABCC gene) have an atypical
structure with five domains. They contain a typical four domain structure, preceded by an
extra NH2-proximal MSD domain composed of five membrane spanning helices (MSDMSD–NBD–MSD–NBD) (Fig. 1. A) (Bakos et al., 1996; Hipfner et al., 1997).
NBDs, considered as the sites for ATP recognition, binding and hydrolysis, are
located on the cytoplasm side of the membrane (Higgins et al., 1986). For most ABC
transporters, each NBD contains three highly conserved sequence motifs: the Walker A,
the Walker B and the Signature C. The specific amino acid residues in either the Walker
A or the Walker B are considered to be important for the ATP hydrolysis. Studies showed
that changes in these residues would abolish the ATP hydrolysis of Pgp (Hrycyna et al.,
1999). The signature motif has been linked to the conduction of energy from ATP binding
and hydrolysis to the transmembrane regions, leading to the conformation changes and
the substrate translocation in the transmembrane regions (Hyde et al., 1990).
MSDs contain the substrate binding sites. The structural divergence in these sites
may result in differences in substrate specificities among ABC transporters (Chang,
2003). Studies have shown that Pgp contains at least two different binding sites or one
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large complex binding bucket (Boer et al., 1996; Pascaud et al., 1998; Ferte, 2000), which
may interact in a positively cooperative fashion (Shapiro and Ling, 1997). Mutually
stimulated transport has been observed in Pgp for transport of Rhodamine and
progesterone (Shapiro and Ling, 1997; Shapiro, 1999).

Figure 1.1 - Predicted secondary structures of ABC transporters for (A) Mrp1 and Mrp2
and (B) P-glycoprotein. MSD, membrane spanning domain; NBD, nucleotide binding
domain; CL, cytoplasmic loop (Modified from Leslie et al., 2005).
Classic membrane transporters usually move the substrate from the aqueous
cytosol to the extracellular aqueous space via an aqueous pore. This pump model is not
supported by Pgp mediated transport across the plasma membrane. It is clear that Pgp
takes hydrophobic substrates from the lipid phase within the inner leaflet of the bilayer
membrane (Stein et al., 1994). The substrate must interact with the lipid phase of the
bilayer membrane before reaching Pgp. Based on these findings, a hydrophobic vacuumcleaner model has been proposed for Pgp transport in which chemicals are extracted
directly from the membrane to the extracellular medium (Higgins and Gottesman, 1992).
But this model can not adequately explain the means by which Pgp specifically binds to
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different substrates (Liu and Sharon, 1996). Thus, another hypothesis has been proposed
that Pgp acts as a flippase, moving chemicals against an intramembrane concentration
gradient from the inner leaflet to the outer of the plasma membrane where they can
diffuse to the aqueous medium (Gottesman and Pastan, 1993). This model provides some
basis for understanding the specificity of Pgp by considering compound interactions with
lipid membranes.
Substrate Specification
One unique characteristic of Pgp and Mrp is their broad substrate specificity. The
therapeutic drugs transported by Pgp include many anti-cancer agents (Gottesman and
Pastan, 1993), HIV protease inhibitors (Lee et al., 1987), immunosuppressants (Meador
et al., 1987), antibiotics (Horio et al., 1989) and steroids (Ueda et al., 1992). Besides
drugs, a number of environmental contaminants have been identified as substrates of Pgp,
including carcinogen 2-acetylaminofluorene (AAF), the hydrophobic xenobiotics Aroclor
1254, DDT, DDD, and DDE, and the hydrophobic pesticides dacthal, chlorbenside,
sulfallate and pentachlorophenol (Kurelec and Pivcevic, 1991; Cornwall et al., 1995;
Galgani et al., 1996; Kurelec et al., 1996). The most common properties shared by these
compounds are moderately hydrophobic or amphiphilic, low molecular weight, positively
charged or neutral compounds with a planar structure (Gottesman and Pastan, 1993;
Kusuhara et al., 1998). The prototypic substrates of Pgp, such as Vinca alkaloids,
anthracyclines, epiodophyllotoxins, rhodamine dyes (Argast and Beck, 1984; Sharom,
1997) and doxorubicin (Mealey et al., 2002), are amphiphilic compounds with a fourringed structure. This structure and physical properties may enhance partitioning into the
cell membrane and the active interaction with Pgp (Bain et al., 1997).
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Mrp mainly effluxes conjugates of organic anions with glutathione, glucuronide
and sulfate (Konig et al., 1999; Leslie et al., 2001). Pgp primarily transports drugs to
which it confers resistance, while Mrp acts cooperatively with conjugate enzymes such as
the glutathione S-transferases and UDP-glucronosyltransferases to confer resistance to
drugs (Depeille et al., 2004; Smitherman et al., 2004). The conjugates of environmental
toxins and drugs identified as Mrp substrates include aflatoxin B, metolachlor,
chelerythrine, arsenic and vincristine (Leslie et al., 2004; Loe et al., 1997; Lou et al.,
2003). The conjugated metabolites are generally thought to be less reactive and toxic as
compared to unconjugated toxins. However, Mrp efflux prevents cellular accumulation of
these conjugated chemicals, which may result in reformation of the active parent
compounds, or direct inhibition of conjugation enzymes and other important enzymes for
the cell viability (Leslie et al., 2005). In humans, the lack of Mrp2 transport function
may lead to Dubin–Johnson syndrome, associated with impaired biliary excretion of
bilirubin glucuronides and other anionic conjugates (Kajihara et al., 1998; Toh et al.,
1999).
MDR/MXR Inhibition
Broad substrate specificity provides an advantage for Pgp to deal with a wide
range of potentially toxic agents. However, Pgp transport may be inhibited when too
many substrates or noncompetitive inhibitors are present. Pgp inhibition may result in an
increase in the systemic bioavailability and bioaccumulation as well as changes in tissue
distribution.
Pgp is thought to have more than one substrate binding site and two ATP binding
domains, which interact cooperatively as a functional unit (Lin, 2003). Inhibitors may
interfere with Pgp at different sites. Verapamil has been shown to inhibit transport
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function of Pgp in a substrate competitive manner (Ford, 1996). Some modulators are not
in fact substrates of Pgp but may inhibit Pgp transport indirectly. Certain
organophosphorus and organochlorine pesticides which have high affinity to bind Pgp,
but are not transported can disrupt the Pgp activity (Bain and Leblanc, 1996). Vanadate
binds with the ATP-binding sites of Pgp without blocking substrate binding, while
cyclosporine A inhibits Pgp activity by interfering with both substrate recognition and
ATP hydrolysis (Ramachandra et al., 1998; Tamai et al., 1991).
Recent studies indicated that Pgp transport activity is particularly sensitive to
changes in the physicochemical state of membrane lipids, especially those surrounding
Pgp (Callaghan et al., 1997; Doige et al., 1993). ATPase activity of Pgp, directly linked
to Pgp transport activity, could be changed by addition of membrane fluidizers such as
ethanol and detergents (Doige et al., 1993; Regev et al., 1999). The modulation of Pgp
ATPase activity here may result from conformation changes induced in the
transmembrane region and transmitted to ATP binding domains (Ferté, 2000).
Furthermore, some evidence suggests that ATP binding sites, which were usually
depicted as extending to the cytosol, could be physically close to the membrane surface.
Alterations of the membrane state may directly affect ATPase activity of Pgp (Liu and
Sharom, 1998).
Environmental contaminants have been found to inhibit Pgp activity in marine
and freshwater concentrates, sediment, soil, industrial or household waste extracts,
hospital waste, Diesel-2 oil and algal extract (Smital et al., 2004). These chemicals
classified as chemosensitizers may increase bioaccumulation of environmental toxicants
and toxicity sensitivity in cells and organisms through inhibition of Pgp transport
(Kurelec, 1995). Studies with mussels (M. galloprovincialis) showed that exposure to
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Diesel-2 oil resulted in accumulation of 3H-vincristine (VCR) threefold greater than upon
exposure to VCR alone (Kurelec and Pivcevic, 1991).

Likewise, mussel embryos (M.

edulis) which were exposed to vinblastine, mitomycin-C, cytocholasin D, chloroquine, or
colchicine showed an increase in number and severity of deformities after verapamil
addition (McFadzen et al., 1999).
MDR/MXR Induction
Exposure to drugs or contaminants frequently leads to the acquisition of
xenobiotic resistance mechanisms, which may act as a generalized response to cellular
stress (Bard, 2000). A wide range of chemicals have been observed to induce MDR1
mRNA and Pgp, regardless if they are Pgp substrates or not. These agents include
anticancer drugs (Chaundhary and Roninson, 1993), DNA-damaging agents ( Fardel et al.,
1998), tumor necrosis factor alpha (TNF-α) (Hirsch-Ernst et al., 1998) as well as
environmental

contaminants

such

as

2-acetylaminofluorene,

aflatoxin

B1,

Benzo[a]pyrene and 3-methylcholanthrene (3-MC) (Fairchild et al., 1987; Chin et al.,
1990; Gant et al., 1991; Doi et al., 2000).
Regulation of Pgp expression in response to inducers has been extensively studied
in vitro and in vivo (Moore et al., 2000; Staudinger et al., 2001). Most evidence points to
an orphan nuclear receptor, pregnane X receptor (PXR), which plays a central role in the
regulation of expression of Pgp as well as CYP2 and CYP3A (Kretschmer and Baldwin,
2005; Handschin and Meyer, 2005). The PXR was named after a class of steroid,
pregnane, which can activate this receptor. Besides pregnane, a broad range of
structurally unrelated compounds, including drugs rifamipicin, dexamethasone and
heperofin, as well as environmental contaminants dieldrin, DDT, DDE and endosulfan
(Lemaire et al., 2004; Coumoul et al., 2002; Wyde et al., 2003), activate PXR. PXR is
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expressed in the liver, intestine and brain (Harmsen et al., 2007). In response to
activation, PXR forms a heterometer with the retinoid X receptor (RXR), which
subsequently binds to the promoter region of the target genes such as MDR1, Mrp and
CYP3A genes, and stimulates transcription (Timsit and Negishi, 2007).
Although PXR plays a key role in Pgp induction, other mechanisms such as gene
amplification, transcriptional control and post translation modifications, are all possibly
involved in increased expression of Pgp in response to inducers (Bard, 2000; Lin, 2003).
MDR1 gene amplification has been observed in some resistant cell lines (Roninson et al.,
1986), but is not required for increased expression of Pgp (Shen et al., 1986). Posttranscriptional controls, such as phosphorylation state and increased mRNA
stability/decreased mRNA half-life, are also important for MDR1 expression. Studies
have demonstrated that phosphorylation of serines and threonines on Pgp is associated
with elevated drug resistance in mammalian cell lines (Ratnasinghe et al., 1998).

MEMBRANE PERMEABILITY
Membrane permeability is the ability of compounds to move across the biological
membrane. Permeation across the cell membranes takes place by three main mechanisms:
passive diffusion, passive transport (channels or carriers) and active transport (carriers).
Diffusion across the cell membrane constitutes the most important mechanism, by which
xenobiotics cross the membrane (Malkia et al., 2004).
The extent of membrane permeability is largely governed by the physiochemical
properties of xenobiotics. Lipophilicity is a crucial factor for membrane permeability of
chemicals (Ayrton and Morgan, 2001). Other molecular characteristics such as molecular
size, charge, volume, hydrogen-bonding capacity may alter the diffusion rate across the
biological membrane (Hilgers et al., 1990, Camenisch et al., 1996). On the other hand,
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diffusion of xenobiotics is also influenced by membrane lipid composition, structural
integrity, membrane thickness and cytosolic characteristics (Fine et al., 2001; Kleinow,
2006).
Membrane Permeability and MDR
Membrane permeability and Pgp transport function are interdependent and for all
practical purposes inseparable. The functional vectorial transport of substrates in an
efflux fashion by Pgp has been clearly shown to be dependent on the passive permeability
of the membrane to the transported substrate in the opposite direction (Eytan et al., 1996
and 1997). Compounds considered to be non-transported modulators of Pgp exhibit
greater permeability and inward diffusability (Scala et al., 1997; Mülder et al., 1995). For
these compounds, if efflux transported by Pgp, movement may be unrecognizable due to
the membrane’s inability to maintain the transporter generated gradient and will allow
concentration dependent compound back-diffusion (Barnes et al., 1996; Fert’e, 2000).
Rho-123, a prototypic substrate of Pgp, on the other hand, demonstrates restricted
membrane movement and vectorial efflux transport is evident (Speelmans et al., 1994;
James et al., 1977). Ccompetitive Pgp modulators like verapamil are more lipophilic and
diffusible than other substrates effluxed by Pgp, allowing diffusion back into the cell
(Sharom, 1997). Therefore, the degree of membrane permeability for a compound is a
determinant of net transport.

XENOBIOTICS: ENVIRONMENTAL RELEVANCE AND
INTERACTIONS WITH ABC TRANSPORTERS
Dieldrin
Dieldrin is a chlorinated cyclodiene compound belonging to a class of synthetic

organochlorine pesticides (Fig. 1.2) (Hassell, 1990). It was first synthesized in 1946 and
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distributed commercially as an alternative to DDT (Dichloro-Diphenyl-Trichloroethane)
in 1950. Dieldrin was broadly used as an insecticide around the world in the middle of
1970s, mainly for the control of tsetse flies and soil pests and for the treatment of seeds.
Dieldrin was listed as one of the 12 most persistent bioaccumulative and toxic (PBT)
pollutants by the US Environmental Protection Agency (US EPA, 2001) and one of the
top 20 hazardous substances to humans (ATSDR, 2005). Due to its extreme persistence
and toxicity, US EPA finally banned the use of this insecticide in 1987. However, it is
still used in a few developing countries (Suwalsky et al., 2002).
Even though banned from use for decades in most of the world, significant levels
of dieldrin continued to be found in soil, water, and biota because of its low volatility and
chemical stability (ASTDR, 1987). An epidemiological study conducted in Taiwan
revealed dieldrin at concentrations of 0.12–5.8 μg/kg sediment (dry weight) in the
impacted river (Doong et al., 2002). In Japan, low levels of dieldrin and other pesticide
residues were observed in 32% of domestic agricultural products and 51% of imported
products (Akiyama et al., 2002). In India, high levels of dieldrin (> 1 μg/g) in vegetables
were reported (Kannan et al., 1997), suggesting higher contamination levels in
developing countries. Animals and humans may be exposed to this compound through
the food chain and direct contact (ASTDR, 2002). Recently, the high levels of dieldrin
have been found in farmed salmon fish worldwide (Hites et al., 2004). An investigation
on human exposure to dieldrin demonstrated that farmers in Iowa have significantly
higher serum dieldrin concentrations. In this case, dietary dieldrin is a major route for
human exposure (Brock et al., 1998).
Effects of organochlorine compounds on Pgp transport have been investigated,
but the results were equivocal. Organochlorine compounds including DDT, DDD and
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DDE, have been shown to reduce the efflux transport of the prototypic Pgp substrate
Rhodamine B from the gills in the marine mussel M. galloprovinvialis (Galgani et al.,
1996). However, DDT, DDE and dieldrin had no effect on the intracellular accumulation
of another Pgp substrate doxorubicin in the murinne melanoma cell lines infected with
human MDR1 gene (Bain and Leblanc, 1996). Inconsistency was also observed with in
vitro studies in gill cells of different mussel species. DDT, DDD, DDE, and
polychlorinated biphenyl--Aroclor 1254 all inhibited the efflux of Rhodamine dye from
the gill cells in one species of mussel (Mytilus galloprovincialis) (Galgani et al., 1996),
but showed no effect on Pgp transport activity in another species (Mytilus californianus)
(Cornwall et al., 1995). The reasons for this inconsistency are still not clear, and may
result from tissue, dosage, species, or other experimental differences.

Figure 1.2 - Chemical structure of dieldrin (Modified from Hassell, 1990).
Previous studies demonstrated that chronic dieldrin treatment altered hepatic
disposition of
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C-dieldrin and 3H-7, 12-dimethylbenz[a]anthracene (DMBA) (Gilroy et

al., 1993 and 1996) and increased biliary excretion of 3H-DMBA and

14

C-B(a)P in

rainbow trout (Donohoe et al., 1998; Barnhill et al., 2003). These results were evident
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without induction of xenobiotic metabolizing enzymes, suggesting that another
mechanism, such as transport actions, may be operative with these findings. In addition,
in vivo studies have shown increased expression of Pgp following exposure of another
organochlorine compound DDE in the gill tissues of the mussel Mytilus californianus
(Eufemia and Epel, 2000). These findings suggest that dieldrin may induce Pgp
expression.
Furthermore, dieldrin and other organochlorine compounds, such as DDT, DDE
and endosulfan have been shown to interact with pregnane X receptor (PXR), which
plays a central role in the regulation of induction of CYP2 and CYP3A as well as Pgp
(Kretschmer and Baldwin, 2005; Handschin and Meyer, 2005). Exposure to these
compounds has resulted in induction of CYP3A and CYP2B in mammary cells (Lemaire
et al., 2004; Coumoul et al., 2002; Wyde et al., 2003). These findings suggest that
dieldrin may have a potential to induce Pgp expression through activation of PXR.
In summary, dieldrin as one of the persistent organic contaminants may have
potential to inhibit or induce Pgp.
Tetracycline
The tetracycline antibiotics, a group of four-ringed amphoteric compounds (Fig.
1.3), are commonly used as a broad-spectrum antimicrobial agent to inhibit the growth of
bacteria, protozoa and intracellular organisms in human and veterinary medicine. In
1970, oxytetracycline was approved by the US FDA for use to treat bacterial infections in
salmons and catfish consumed by humans (Plakas et al., 1998). Tetracycline may be
administered through an intravenous, intramuscular, or oral pathway. Once absorbed,
tetracycline is widely distributed throughout the body and then accumulated in the liver
and kidneys. Tetracycline is not significantly metabolized in the body and mainly
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eliminated as parent compounds through feces and urine (Aronson, 1980). Enterohepatic
circulation may occur with tetracycline (Kunin and Finland 1961).
Bacterial resistance to antibiotics often occurs during the clinical treatment. It
involves two major mechanisms: the bacterial cell wall permeability barrier and the
active multidrug transport proteins (De Rossi et al., 2006). The active transport proteins
found in bacteria exhibit a high degree of sequence homology with Pgp (Chen et al.,
1986; Neyfakh 1997) and similar characteristics to the multidrug resistance system in
mammalian cells (Neyfakh et al., 1991). Studies performed in bacteria revealed that
MDR gene transfection resulted in reduced intracellular accumulation of tetracycline
(Levy, 1992; George et al., 1996; Chollet et al., 2004). In addition, cyclosporine A and
verapamil, the competitive inhibitors of Pgp, completely reversed tetracycline resistance
and increased accumulation of tetracycline in the human leukemic cells expressing
MDR1 gene (Kavallaris et al., 1993). A tetracycline derivative doxycycline has also been
shown to potentially inhibit transport activity of Pgp and induce overexpression of Pgp in
MCF-7 breast carcinoma cells (Kavallaris et al., 1993).

Figure 1.3 – Chemical structure of tetracycline.
Surfactants
Surfactants (surface-active agents) are a diverse group of chemicals designed for
cleaning and/or solubilization. They are usually amphiphilic organic compounds
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containing both hydrophobic parts (their nonpolar tails) and hydrophilic parts (their polar
heads). Therefore, they are readily soluble in both organic solvents and water. These
compounds are widely used for domestic and industrial applications, such as household
cleaning, personal care products, paints, and paper industries. These agents are also
employed as adjuvants in pesticide and pharmaceutical formulations and as dispersants in
the remediation of soil contaminated by heavy metals and PAHs. (Burchfield et al., 1994,
Baran Jr. et al., 1998; Cowell et al., 2000). Due to their widespread use, the world
consumption of synthetic surfactants reached up to 7.2 million tons annually (Di Corcia,
1998).
Linear Alkylbenzene Sulfonates (LAS)

Figure 1.4 - Chemical structure of linear alkylbenzene sulfonate (LAS) where x plus y
equals 7 to 11 depending on the length of the alkyl chain (Adapted from Trehy et al.,
1996).
Linear alkylbenzene sulfonate (LAS), the most popular synthetic anionic
surfactant, constitutes more than 40% of total surfactants in the detergent industry (Verge
et al., 2001). The basic structure of LAS is a benzene ring connected to an alkyl chain
with different lengths ranging from 9 to 13 carbon units (the nonpolar tail) and a sodium
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sulfate group (the polar head) (Fig. 1.4) (Trehy et al., 1996). Commercial products of
LAS are very complex mixtures consisting of different homologues.
After use and disposal, LAS may directly reach surface water, sediment and soil,
or be discharged as residuals from sewage treatment plants (Jensen, 1999). LAS are
readily biodegradable under aerobic conditions (Perales et al., 1999). However, due to the
widespread use and high consumption, various levels of LAS have been detected in the
aquatic environments. LAS has been found in sewage effluents and in surface waters in
the UK (1090 and 416 μg/l) (Holt et al., 1998; Fox et al., 2000) as well as in the effluents
of wastewater treatment plants in the US (4 to 94 μg /l) (Trehy et al., 1996). LAS has also
been reported at concentrations of 20 to 1000 μg/l in outlets to estuaries and near-shore
marine waters in the North Sea (Berna et al., 1991; Stalmans et al., 1991), and 0.1 to 2.8
μg/l in Mississippi River water (Tabor and Barber, 1996). LAS levels in sediments have
been reported to be much higher than in water due to much lower degradation rates under
anaerobic conditions. 49-129 µM LAS/kg dry weight (dw) is reported in sediments in the
Tsurumi River, Japan (International Program on Chemical Safety, 1996), and 0.11-0.30
µM LAS/kg dw in the German Bight of the North Sea (Berna et al., 1991; Stalmans et al.,
1991).
Studies in fish revealed that LAS is mainly absorbed through gills, rapidly
distributed throughout the body, highly concentrated in gills, blood, hepatopancreas and
kidneys, and primarily eliminated through bile (Kikuchi et al., 1978). In general,
surfactants cause disruptions of the biological membrane and denaturation of membrane
proteins (Swisher, 1987; Schwunger and Bartnik, 1980). Exposure to high concentrations
of LAS results in inhibition of mobility, reproduction and growth, and even death of fish
(Verge et al., 2001; Utsunomiya et al., 1997; Hofer et al., 1995; Singh et al., 2002). The
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No Observed Effect Concentration (NOEC) and the Predicted No-Effect (PNEC) of LAS
for freshwater were 200 and 360 µg/l, respectively. As the thresholds of the defined acute
and chronic toxicity for LAS in aquatic organisms are much higher than the measured
environmental levels, the direct toxic effects of LAS are assumed to be low in the
environment (Ying GG, 2005; Scott and Jones, 2000). As a common environmental
pollutant, LAS often exists in mixtures with other contaminants. Mixtures of toxicants
containing LAS may result in additive or even synergistic effects on fish and other
organisms (Lewis, 1992). Several early studies have shown that LAS exposure resulted in
enhanced uptake and altered disposition of other compounds such as phenol (Mann,
1962), pesticide parathion (Solon et al., 1969) and metals (Pärt et al., 1985, Calamari and
Marchetti, 1973). These findings are linked to alterations of membrane permeability by
surfactants.
Surfactants and Multidrug Resistance
Surfactants have been extensively employed as excipients in the pharmaceutical
formulations to facilitate drug absorption (Rege et al., 2002).

Initially, they were

considered as physiologically insert compounds for enhancing drug solubility. However,
recent studies suggested that these compounds may insert into the lipid membrane to
varying degrees, and increase membrane fluidity (Sinicrope et al., 1992; Woodcock et al.,
1992; Swenson et al, 1994), disrupt tight junctions between the epithelial cells (Aungst
2000; Anderberg et al., 1992), and interact with metabolic enzymes (Mountfield et al.,
2000). Moreover, they have been shown to inhibit the efflux activity of ABC transporters
Pgp and Mrps (Bobrowska-Hagerstrand et al., 2003; Ellis et al., 1996; Orlowski et al.,
1998; Strugala et al., 2000). The modulation of Pgp and related ABC transporters is of
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particular interest as their critical role in xenobiotic accumulation and disposition in the
body.
Surfactants including Cremophor EI, Solutol HS15, Triton X-100, Nonidet P-40
and Pluronic block copolymers, have been observed to increase accumulation and
cytotoxicity of antineoplastic agents in tumor cells overexpressing Pgp and in vivo mice
carrying with MDR tumors (Batrakova et al., 1996; Webster et al., 1993; Dudeja et al.,
1995; Buckingham et al., 1995; Zordan-Nudo et al., 1993). Recently, pluronic polymer
bound doxorubicin has been developed and undergone phase I clinical trials to treat MDR
tumors (Danson et al., 2004). Surfactant-induced MDR inhibition not only occurred in
MDR tumor cells, but also in normal tissues such as in liver (Ellis et al., 1996), intestine
(Strugala et al., 2000) and blood brain barrier (Miller et al., 1997).
The mechanism by which Pgp transport is inhibited by surfactants has been
investigated. Tween 80 and nonylphenol ethoxylates (NPEs) have been shown to inhibit
Pgp transport by blocking the substrate binding to Pgp (Yamazaki et al., 2000; Friche et
al., 1990; Doo et al., 2005). Batrakova discovered that surfactant Pluronic P85 was able
to permeate the membrane of mitochondria, disrupt oxidative phosphorylation and lead to
ATP depletion in the cell (Batrakova et al., 2001). Krylova and Pohl demonstrated that
Puronic L61-induced ionic flux in the plasma membrane could result in compensatory
ATP consumption by Na+-K+ ATPase and decreased cellular ATP levels (Krylova and
Pohl, 2004). Studies with lipids and detergents indicated that perturbation of the
membrane environment may alter Pgp transport function (Ferté, 2000; Doige et al.,
1993). These agents may change lipid mobility and structure in the plasma membrane,
and consequently affect conformational changes of membrane bound protein Pgp (Rege
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et al., 2002; Regev et al., 1999), which may be associated with Pgp’s ATPase activity (Lu
et al, 2001).
Likewise, surfactants may modulate Mrp and other membrane enzymes since they
have potential to interfere with Pgp through membrane perturbation. Studies have shown
that surfactant pluronic copolymer has inhibitory effects on Mrp transport (Miller et al.,
1999). Activities of membrane enzymes such as CYP3A and glutathione-S-transferase
(GST) system were also decreased in the presence of surfactants (Johnson et al., 2002;
Batrakova et al., 2004).
In addition, substrates of Pgp and Mrp are lipophilic or amphiphlic, which enter
the cell via passive diffusions through the plasma membrane. The cellular accumulation
of these compounds in MDR cells relies on membrane permeation properties as well as
on the handling by the ABC transporters (Ferté, 2000). Surfactants, as amphipathetic
molecules, whose structures imitate that of endogenous glycerophospholipids, are able to
insert themselves between lipophilic tails of membrane bilayers, resulting in disorder of
the lipid-packing arrangement of membranes. The net result is that the membrane
becomes fluidized, facilitating the passive diffusion of compounds across the membrane
(Lo, 2003), and thereby increasing membrane permeability and cellular accumulation
(Drori et al., 1995; Hendrich and Michalak, 2003).
Surfactants are common environmental pollutants and mixture components in
aquatic systems. Therefore, it is of interest to determine if surfactants at environmentally
relevant concentrations may influence bioavailability or bioaccumulation of other more
hazardous xenobiotics present in environmental mixtures through these actions.
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Ivermectin
Ivermectin (IVM) (22, 23-dihydroavermectin B1a + B1b) are the semi-synthetic
derivatives from Streptomyces avermilities, consisting of a disaccharide linked to a
macrocyclic lactone (Fig. 1.5) (Roberts and Hutson, 1999). It is a broad-spectrum
antiparaside extensively used in veterinary and human medicine. In United States, IVM is
approved for use in swine, cattle, sheep, goats, bison, reindeer, and horse. Recently, it has
been applied to treat the sea lice in salmon (Stone et al., 2000). IVM primarily acts on the
nervous system of parasites. It binds to glutamate-gated chloride channels and GABA (camino butyric acid)-gated chloride channels, increases chloride influx, and results in
hyperpolarization in nerves and muscle cells (Martin 1997). This disrupts neural signal
transmission and paralyzes neuro-muscular junctions in organisms ultimately leading to
death (Mellin et al., 1983).

Figure 1.5 - Chemical structure of ivermectin (IVM) (Adapted from Roberts and Hutson,
1999).
At therapeutic doses, IVM does not affect mammals since glutamate and GABA
synapses are located in the central nervous system (CNS), which is largely protected from
the blood-brain barrier (Campbell et al., 1983). However, some dog species, most notably
the collie, exhibit signs of CNS toxicity at IVM doses much lower than the normal
therapeutic dose. The cause of CNS toxicity in susceptible dog species has been linked to
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a mutation in a MDR1 gene (Mealy et al. 2001). High expression of Pgp in the blood
brain barrier may protect the brain tissues from the penetration of IVM and its
neurotoxicity (Schinkel et al., 1994). Several studies demonstrated that IVM interferes
with Pgp as a substrate (Alvinerie et al., 1999; Ballent et al., 2006). Pgp modulators
including verapamil, loperamide, PSC833 and itraconazole, have been shown to increase
its IVM plasma and tissue concentrations after co-administration (Alvinerie et al., 1999;
Lifschitz et al., 2004; Ballent et al., 2006). On the other hand, multidrug resistance in
tumor cells has been reversed by IVM (Korystov et al., 2004).

All these findings

suggested that Pgp plays a critical role in absorption, dispositions and bioavailability of
IVM.
Since its action mode is not limited to parasites, IVM may affect other organisms
in the environment. In fish studies, it has been reported that IVMs were distributed
extensively to the brain (Høy et al., 1990), indicating that fish have poorly developed
blood brain barrier as compared to mammals and may be susceptible to IVM toxicity.
IVM has also been shown to produce adverse effects on reproduction, biological function
and survival of non-target aquatic and terrestrial organisms (Halley et al., 1993; Steel and
Wardhaugh, 2002).
As a widely used veterinary drug, IVM may enter environmental waterbodies and
fish through aquaculture practices, runoff /leaching from concentrated on-ground fecal
material and municipal sources (Daughton and Ternes, 1999). Following administration,
IVM is excreted mainly as a parent compound or active metabolites through faeces
(McKellar and Benchaoui, 1996; Lumaret and Errouissi, 2002). The physicochemical
properties of IVM are low water solubility, high molecular weight and high Kow
(McKellar, 1997). Therefore, once discharged in the environment, it is readily absorbed
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by organic matter, soil, sediment particles and fish. It may be rapidly photodegraded in
water to less bioactive compounds by oxidative mechanisms (Halley et al. 1993).
However, due to its high volume and frequent use, IVM is of concern for its
environmental toxic effects and potential risks to human health through the food chain
(Tisler et al., 2006).
Benzo[a]pyrene
Benzo[a]pyrene (BaP) is a ubiquitous procarcinogen, belonging to the family of
the polycyclic aromatic hydrocarbons (PAHs). BaP and other PAHs occur as a byproduct
of incomplete fossil fuel combustion such as in coke ovens, automobile exhaust, cigarette
smoke, and charcoal grilling of food. Spills and accidents during the production and the
transport of oil constitute another major source of BaP in the environment (ASTDR,
1990). PAHs are frequently found in impacted aquatic environments, especially in
contaminated sediments (EPA, 1991). In a designated superfund site of New Bedford
Harbor, USA, concentrations of PAHs have been reported to up to 170 μg/g dry weight in
sediments (Pruell et al., 1990).
Dietary BaP is an important route of exposure for aquatic species and humans as
a consequence of movement of BaP and its metabolites along the food chain (Kleinow et
al., 1998; Hattemer-Frey and Travis, 1991). Human exposure to BaP through the food
chain has been shown to account for about 97% of the total daily intake (Hattemer-Frey
and Travis, 1991). Fish inhabiting polluted waters containing PAH are likely to be
exposed in the diet to PAHs and their metabolites in the food item (e.g. smaller fish or
plants) (James et al., 2001). High concentrations of BaP in fish food products have been
detected over the past decades (Loutfy et al., 2007).
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BaP is a moderately lipophilic neutral compound. It is readily absorbed by aquatic
animals from the gastrointestinal tract (Varanasi et al., 1989) and rapidly distributed to
well-perfused organs in the body (Tyler et al., 1981).

BaP is primarily eliminated as

water-soluble metabolites through hepatobiliary excretion and feces. Biotransformation
of BaP can occur in two main phases. The phase I reaction involves interactions with
mixed-function oxidases, especially the cytochrome P450s, and formations of diolepoxides, including B(a)P-7,8-dihydrodiol-9,10-oxide (BPDE), the major carcinogenic
metabolite. In phase II reactions, various polar moieties such as glutathione (GSH),
sulfate and glucuronic acids are conjugated to the phase I intermediate metabolites (Di
Giulio et al., 1995; Leonard et al., 2001). As a result, only minor parent BaPs remain in
body tissues (Di Giulio et al., 1995). The liver is regarded as the major site of metabolism
for BaP, although the significant metabolism may occur in gastrointestinal tract, skin and
lung (Perera, 1981).
BaP is carcinogenic, mutagenic, teratogenic, and cytotoxic to various cells and
organisms (Conney et al., 1994 ; Miller and Ramos, 2001). BPDE, the major reactive
metabolite of BaP, is able to interact covalently with biological macromolecules (e.g.,
DNA, proteins) and form adducts (Hall and Grover 1990; Varanasi et al, 1989).
Alternatively, BaP’s ultimate carcinogenic metabolite (BPDE) may be detoxified by GSH
conjugation, which is catalyzed by glutathione S-transferase (Robertson et al., 1986).
Previous studies suggest that BaP itself is probably not a substrate of Pgp
(Schuetz et al., 1998). However, BPDE conjugates have been shown to be actively
transported across the canalicular plasma membrane and intestinal Caco-2 cells (Buesen
et al., 2003; Srivastava et al., 1998). The accumulation of BPDE and its GSH conjugates
is enhanced by reduction of MRP2 transporter function (Srivastava et al., 2002),
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suggesting that MRP2 may play an important role in elimination of conjugated BaP
metabolites. Therefore, in addition to GSH conjugation, the efflux of the conjugates of
BPDE is essential for the cellular protection against BPDE-induced toxicity.
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CHAPTER 2: EFFECTS OF DIELDRIN ON THE
PHARMACOKINETICS AND DISPOSITION OF TETRACYCLINE
IN IN SITU ISOLATED LIVER PREPARATIONS AND IN VIVO
CHANNEL CATFISH VIA INTERACTIONS WITH
P-GLYCOPROTEIN
INTRODUCTION
P-glycoprotein (Pgp) is an ATP-dependent efflux membrane protein belonging to
the ATP-binding cassette (ABC) transporter superfamily, which plays a pivotal role in
absorption, disposition and excretion of various drugs (Juliano et al., 1976; Ambudkar et
al., 1999). It is found in a variety of tissues, including the luminal face of intestine and
brain capillaries, and the apical membrane of liver and kidneys (Aryton and Morgan,
2000). Its location in organs of absorption, the blood-brain interface and elimination
suggests Pgp plays a role in the barrier function, tissues distribution and excretion of
drugs (Wacher et al., 2001; Frohlich et al., 2004). Pgp transports various therapeutic
drugs (Lin, 2003), certain food constituents (Balayssac et al., 2005), as well as a variety
of contaminants (Galgani et al., 1996; Toomey et al., 1996; Bard, 2000; Leslie et al.,
2005).
Numerous environmental xenobiotics have been shown to increase accumulation
of Pgp substrates via inhibition of Pgp transport activity either as substrates or as
noncompetitive inhibitors. Four hydrophobic pesticides including dacthal, chlorbenside,
pentachlorophenol, and sulfallate have been shown to reduce Pgp-mediated Rho-123
efflux from special gill cells in the mussel Mytilus galloprovincialis (Cornwall et al.,
1995; Galgani et al., 1996). Likewise, in mussels (M. galloprovincialis), exposure to
Diesel-2 oil increased accumulation of the Pgp substrate, [3H]-vincristine (VCR)
threefold (Kurelec, 1995). Induction of Pgp has been observed following exposure to
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environmental

contaminants.

Polycyclic

aromatic

hydrocarbons,

including

benzo[a]pyrene (BaP) and 3-methylcholanthrene (3-MC) (Fardel et al., 1996), and the
carcinogen 2-acetylaminofluorene (AAF) (Chieli et al., 1995; Tateishi et al., 1999)
increased expression of Pgp in rat hepatocytes. Similarly, in vivo studies have shown
induction of Pgp in intestine following exposure to the xenobiotic β-naphthoflavone
(BNF) in catfish (Kleinow et al., 2000) and rat and human (Lown et al., 1996). As a
result, pharmacokinetics, efficacy and bioavailability of drugs by which disposition is
mediated by Pgp may be altered by environmental compounds, which inhibit or induce
Pgp.
Drug to drug interactions due to inhibition or induction of Pgp are widely
recognized to be of clinical concern in that they may lead to altered pharmacokinetics,
efficacy and bioavailability of Pgp transported drugs (Yu, 1999; Balayssac et al., 2005).
The most overwhelming evidence of this phenomenon in humans is the interaction of
digoxin, a Pgp substrate, with other drugs. When administered a daily dose of verapamil
(160 mg), a substrate and competitive inhibitor of Pgp, a 40% increase in plasma
concentration and a reduction of renal elimination of digoxin were evident (Pedersen,
1985; Verschraagen et al, 1999). In contrast, a 14-day St. John’s exposure led to a
significant increase in fexofenadine clearance, consistent with Pgp induction (Moore et
al., 2000).
As an extremely persistent and toxic organochlorine, dieldrin readily
bioaccumulates in fish, wildlife and humans (ASTDR 2002). Even though banned for all
uses within the United States by EPA (U.S. EPA, 1971 and 1990), it still exists in all
environmental media (U.S. Department of interior, 1999). Humans and animals are
exposed to this compound though the food chain and direct contact (ASTDR 2002).
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Studies have shown that dieldrin is a potent activator of human pregnane X receptor
(PXR) (Coumoul et al, 2002; Lemaire et al., 2004), which is the main regulator for Pgp
and CYP 3A4 expression (Veau et al., 2002; Matheny et al., 2004). In addition, chronic
dieldrin treatment in rainbow trout alters hepatic disposition of [14C]-dieldrin and [3H]-7,
12-dimethylbenz[a]anthracene (DMBA) (Gilroy et al., 1993 and 1996), and stimulate
biliary excretion of [3H]-DMBA and [14C]-benzo[a]pyrene (Donohoe et al., 1998;
Barnhill et al., 2003). These results, without induction of xenobiotic metabolizing
enzymes, suggest that another mechanism, such as transport action, may be operative
with these findings. However, there is still no direct evidence pointing to interactions
between dieldrin and Pgp.
Little evidence exists regarding interactions between environmental contaminants
and drugs via Pgp mechanisms, especially regarding the effects of contaminants on the
pharmacokinetics and bioavailability of Pgp mediated drugs. We hypothesize that the
pharmacokinetics and disposition of Pgp mediated drugs may be altered by contaminants,
which inhibit or induce Pgp. The goal was to investigate the effects of dieldrin on the
pharmacokinetics and disposition of tetracycline, a broad spectrum anti-bacterial drug.
Specific objectives include: 1). to characterize the effect of dieldrin and tetracycline on
Pgp transport activity at the bile canniculi using the prototypic Pgp substrate Rhodamine
123 (Rho-123) in the isolated perfused liver preparation; 2). to evaluate the effect of
diedlrin on biliary excretion of tetracycline and 3). to examine the effect of chronic
exposure to dieldrin on the pharmacokinetics, distribution and excretion of tetracycline as
related to Pgp expression. Tetracycline was chosen in this study for its structural
similarity to Rho-123, the prototypic Pgp substrate (Fig. 2.1), its minimal metabolism in
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Rhodamine-123 (Rho-123)

Tetracycline

Figure 2.1 - Chemical structures of Rhodamine-123 and tetracycline.
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body (Aronson, 1980) and its widespread use in humans and animals. Tetracycline and its
derivatives have been recognized as substrates of Pgp in bacteria (Levy, 1992, Chollet et
al., 2004; Qin et al., 2004) and cultured cancer cells (Mealey et al., 2002). Studies have
shown that the Pgp “like” transporter in fish displays a high degree of sequence
homology (Chan et al., 1992), a similar tissue distribution pattern (Kleinow et al., 2000),
and transport function consistent with that demonstrated in mammals (Schramm et al.,
1995). In the environment, fish are at high risk of being exposed to dieldrin and have
shown a potential to retain dieldrin at high concentration levels in body (Jorgenson,
2001). Catfish were used in this study due to use of tetracycline as a therapeutic in
aquaculture applications (Plakas et al., 1998) and potential exposure to dieldrin.

MATERIALS AND METHODS
Chemicals
Dieldrin (~90%) was obtained from Aldrich Chemical Company, Inc.,
Milwaukee, WI. [3H]-tetracycline (0.906 or 1.07 Ci/mM, >95%) was purchased from
PerkinElmer Life Sciences, Inc., Boston, MA. Tricane methane sulfonate (MS-222) was
provided by Argent Chemical Company, Redmond, WA. Dimethyl sulfoxide (DMSO)
was supplied by Fisher Scientific, Fair Lawn, NJ. Tetrahydrofuran (C8H8O) was provided
by Mallinckrodt, Inc., Pairs, Kentucky. Tissue Solubilizer TS-2 was acquired from
Research Products International Corp., Mount Prospect, IL. Heparin sodium (1000 or
10000 USP units/ml) was acquired from Elkins-sinn, Inc. Cherry Hill, NJ.
Electrophoresis material and the Immuno-Blot™ Assay Kit with Goat Anti-mouse IgG
Alkaline Phosphatase (GAM-AP) were provided by Bio-Rad Laboratories, Hercules, CA.
The C219 murine monoclonal antibody was obtained from Signet Laboratories Inc.,
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Dedham, MA. Rhodamine-123 (Rho-123), tetracycline, verapamil, and all other
chemicals used for buffer preparations were purchased from Sigma, St Louis, MO.
Animals
Male and female channel catfish used in these studies were obtained from the
Louisiana State University Aquaculture Research Station, Baton Rouge, LA. Animals
were grown and maintained at least 2 months prior to use under a flow-through
conditions at 19oC in dechlorinated tap water with a 12 h light/dark photoperiod. A
commercial chow diet (Silvercup trout chow, Sterling Farms, UT) was fed at 0.5 to 1%
body weight per day prior to use in experiments.
[3H]-tetracycline (TET) Dose Preparations
Solid [3H]-tetracycline (TET) (0.906 Ci/mmol or 1.07 Ci/mmol) as obtained from
the manufacturer was diluted with 250 µl of DMSO to form stock solutions. The stock
solutions were further diluted into [3H]-TET solutions (~16 µCi/ml) used in the in situ
experiment, and solutions (52-63 µCi/ml) for in vivo investigations.
Isolated Liver Perfusion Studies
Surgery Procedure
Catfish of both sexes were fasted 24 h prior to surgery. Isolated livers (19.02 ±
5.01 g) were prepared according to the details previously described (Kleinow et al.,
2004). Animals were anesthetized with buffered Tricane methane sulfonate (MS-222) at
induction and maintenance doses of 106 and 86 mg/l, respectively. Following ventral
midline and transverse incisions exposing the liver and gallbladder, the common bile duct
was cannulated with a perforated PE260 tubing with an attached PE50 tubing for bile
collections. Liver vessels were isolated and sutures preplaced. An intravenous catheter
(13-gauge) was then inserted into the portal vein, ligated in place, and connected to a
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gravity fed perfusion system supplying oxygenated and heparinized (10 USP/ml) teleost
Ringer's solution ( 117.2 mM NaCl, 4.8 mM KCl, 0.9 mM CaCl2, 1.5 mM MgSO4, 12.3
mM Na2HPO4, 1.4 mM NaH2PO4, 5 mM glucose, pH 7.4). Once media flow was
established from the afferent cannula to the liver circulation, collateral vessels were
ligated, the cardinal veins transected and the liver cleared of blood. After stabilization,
the liver was removed from the fish while being perfused and placed on the perfusion
apparatus. The perfusion apparatus was set at 12 cm of head pressure to create
physiological pressures for oxygenated perfusate delivery during the experimental
procedure. The isolated perfused livers were maintained at 20oC.
Experiment Designs
Eight groups of five to seven individual fish (1532.5 ± 311.5 g) were prepared for
isolated liver perfusions in two separate experiments. In the first experiment to evaluate
effects of tetracycline and dieldrin on Pgp transport activity, livers were pre-perfused
with oxygenated teleost Ringers’ solutions (1L) containing vehicle alone for 1) control
(N=5), or individual treatments 2) TET (20 μM) (N=5) or 3) dieldrin (20 μM) (N=7).
This process removed the remaining blood and preexposed livers to specific treatment
condition. Following pre-perfusion, the isolated livers were perfused in a recirculating
system for 210 min with 250 ml of media, which were compositionally identical to the
pre-perfusion mixture, except containing 1 μM Rho-123. A similar procedure was applied
to the second experiment to examine effects of verapamil & dieldrin on transport of [3H]TET into bile. The treatment groups were: 1) control (N=6), 2) verapamil (20 µM) (N=5),
3) dieldrin (20 µM) (N=5), using radiolabel [3H]-TET (8.8 nM) as analytes. Samples of
bile and perfusate were harvested at 30 min intervals for the 210 min perfusion.
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In Vivo Studies
Dieldrin Treatment
The effect of chronic dieldrin pretreatment upon Pgp expression and the
pharmacokinetics and disposition of tetracycline were investigated in vivo in the catfish.
All animals were acclimatized to experimental conditions for at least 2 weeks before
dietary treatment. Control and experimental diets were prepared by coating commercial
chow diet using tetrahypofuran (10 ml/kg diet) with or without dieldrin (10 mg/kg diet).
Both stocks were made prior to the beginning of the experiments and stored at -20oC. All
animals were fed diets with or without dieldrin (0.1 mg/kg body weight per day) at 1%
body weight daily for 4 weeks prior to surgery.
Dorsal Aorta Cannulation
The cannulation procedure and animal maintenance after surgery were performed
according to previous details (Kleinow, 1991). Following anesthetization, fish were
weighed and placed in a dorsal recumbence on an aquatic operating table. The aortic
cannula (PE-50 tubing) with an indwelling stylet was placed into the aorta along the
dorsal midline of the fish’s mouth between the first and third branchial arches. The
cannula was attached to the palate mucosa with preplaced sutures and brought dorsally
through the cartilage rostral to the nares. An extension of the cannula was anchored to
the dorsal fin, and filled with heparinized saline (10 IU/ml, 0.9% NaCl). After surgery,
fish were moved to individual holding chambers with flow-through water. Chamber
design and cannula placement allowed for sampling from the free swimming fish.
Animals were held 24h for recovery from anesthesia and clearance of MS-222 before use.
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In Vivo Experiment Dosing, Design and Sample Collection
Two separate experiments were used for in vivo investigations using cannulated
animals. All animals (807.7 ± 93.7) of either sex were administered a single bolus dose of
[3H]-TET at 20 µCi /kg body weight (8.31 µg/kg) through the preplaced aortic cannulas.
The first experiment examined the pharmacokinetics of [3H]-TET with or without
dieldrin (0.1 mg/kg body weight per day for 4 weeks) pretreatment using two groups of
five or six fish. Following administration of [3H]-TET, 400 µl of blood samples were
collected through the cannula at 1, 2, 4, 6, 8, 12, 24, 36, 48, 72 and 96 h after dosing. 120
µl of blood samples were aliquoted and centrifuged for 10 min at 3000×g at 4oC. 50 µl of
plasma aliquots were prepared for radioactivity measurements.
The second experiment examined the tissue distribution and mass balance of [3H]TET as well as the hepatic expression of Pgp using two groups of five or six fish one with
and one without dieldrin (0.1 mg/kg body weight per day for 4 weeks) preexposure. At
72 h after administration of [3H]-TET, fish were euthanized with MS-222 (250 mg/l) to
harvest samples. Bile, liver, spleen, kidneys, heart, intestine, stomach, abdominal lipids,
gills, muscle, eggs and carcass were collected and weighed for total mass balance and
aliqots radioassayed for [3H]-TET molar equivalents in fish. In addition, intestine and
stomach were cut open, inverted, contents rinsed with 0.9% saline; blotted, dried and
homogenized before the sample was harvested and analyzed. The mass of the muscle
tissue was assumed 50% of carcass in this study (Bosworth et al., 2001). Aliquots of
liver tissues (~ 2g) for Pgp expression analysis were harvested immediately following
removal and mass balance, suspended in ice-cold modified Sack’s preservation buffer
(5mM KH2PO4, 14 mM NaHCO3, 54mM K2HPO4, 5.9mM KHCO3, and 205 mM

63

mannitol, pH 7.4), snap frozen in liquid nitrogen and finally stored under -80oC until
analysis.
Rho-123 Assay
Fluorescence of Rho-123 in bile and perfusate samples from isolated livers were
measured with 20 nm slit width at excitation and emission wavelengths of 507 and 529
nm, respectively, on a Hitachi F-2000 Fluorescent Spectrophotometer. Bile samples (20
µl) or those less than 20 µl added zero time-point bile up to a volume of 20 µl, were
diluted with teleost Ringer’s solution to a final volume of 600 µl. Each perfusate sample
(20 µl) was combined with zero time bile (20 µl) and teleost Ringer’s solution to a final
volume of 600 µl. Concentrations of Rho-123 was calculated in dilutions by interpolation
upon a standard curve of Rho-123 concentrations formulated for each fish, using their
individual zero time bile to minimize effects of different bile salt concentrations and
compositions on fluorescence background. If the samples had reading outside of the
standard curve range, they were diluted again up to a final volume of 600 µl, using teleost
Ringer’s solution containing zero time bile (30:1, v/v).
Radioactivity Measurements
Tissue samples (50-100 mg) were digested in 0.5 ml of TS-2 Tissue Solublizer at
50oC for 24 h. Following cooling, the samples were neutralized with 18 µl of glacial
acetic acid and combined with 4.5 ml LSC -cocktail (Ultima Gold, Packard Bioscience,
Meriden, CT). Bile, plasma or perfusate samples (20 µl) were not digested prior to adding
4.5 ml LSC -cocktail. All scintillation samples were dark adapted overnight before
counting. Samples were counted 30 min each on a Tri-Carb Liquid Scintillation Analyzer
(Model 1900 TR). Quench correction, counting efficiency and background were
performed for all samples.
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Pgp Expression Analysis
Plasma Membrane Protein Preparations
Hepatic plasma membrane proteins were prepared as described by Doi et al, 2000.
Hepatic tissue (~ 2 g) were homogenized in 16 ml of ice-cold plasma membrane buffer (5
mM Tris–HCl, pH 7.5, 0.25 M sucrose, and 0.2 mM magnesium chloride), containing 1
mM EDTA and 100 µl of protease inhibitor cocktail (Sigma, St Louis, MO). The
homogenates were centrifuged at 1000×g (Rotor type J25.50, Beckman) for 10 min at
4°C and the resulting supernatant reserved. The pellets were resuspended in plasma
membrane buffer and recentrifuged. Supernatants from both operations were combined
and spun at 15 000×g for 20 min at 4°C. Resulting supernatants were centrifuged at
100000×g in a TI 70 rotor for 1 h at 4°C. Final pellets containing the crude membrane
fractions were resuspended in 1 ml of homogenization buffer. Hepatic membrane protein
content was determined with folin phenol reagent (Lowry et al., 1951).
Western Blot Analysis
The membrane vesicles were subjected to gel electrophoresis, transfer to a
nitrocellulose membrane, blocking and immunoblotting procedures for the detection of
Pgp. Membrane vesicles (30 µg) were diluted (1:5) with sample buffer (62.5 mM Tris,
pH 6.8, 2% SDS, 10% glycerol, and 0.001% bromophenol blue) and maintained at room
temperature for 20 min. Proteins were loaded on a 7.5% acrylamide gel at a constant
voltage of 200 V in running buffer (25 mM Tris–HCl, pH 8.3, 192 mM glycine, and 0.1%
SDS running buffer), using Mini-protean™ II Dual Slab gel system (BioRad). After
electrophoresis, proteins were transferred at 100 V for 2 h onto a 0.45 µg nitrocellulose
membrane with transfer buffer (25 mM Tris, pH 8.3, 192 mM glycine, 20% v/v
methanol). The membrane was then washed twice each for 5 min in Tris-buffered saline
65

(TBS) (20 mM Tris, pH 7.5, 500 mM NaCl) before blocked with 0.1 M Levamisole in
TBS for 1 h. Following three 5-min washes in TBS, the membrane was blocked again
with 3% gelatin in TBS solution and washed for 5 min using 0.05% Tween-20 in TBS
(TTBS). Membranes were then incubated overnight with Pgp C219 monoclonal antibody
(Signet Laboratories Inc.) (0.2 µg/ml) in antibody buffer (1% gelatin in TTBS).
Following two 5-min washes in TTBS, conjugate binding was performed with Goat Antimouse IgG Alkaline Phosphatase (GAM-AP) for 90 min in antibody buffer. Following
washes with TTBS and TBS, immunoreactivity was color developed using nitroblue
tetrazolium in aqueous dimethylformamide with magnesium and 5-bromo-4-chloro-3indoyl phosphate. Molecular weight was determined with protein markers (Kaleidoscope
Prestained Standards, Bio Rad Laboratories Inc.). The staining densities of protein
immunoreactivity were quantified using a VersaDoc Imaging System (Quantity One, Bio
Rad Laboratories Inc.). An internal standard sample was loaded in all gels for
normalization of variability between gels.
Pharmacokinetic Analysis
The plasma concentration versus time course data obtained from administration of
[3H]-TET in catfish was plotted on a semilogarithmic scale. Data were fitted by a twocompartment, bolus-input, first-order output model (model 8), using PCNONLIN 3.0
software (Statistical Consultants, Inc., Lexington, KY, USA). Line fitting for individual
animal data was optimized using least-squares fit. Statistical moment theory was used for
all subsequent pharmacokinetic determinations (Gibaldi and Perrier, 1982). The
pharmacokinetic data were reported as mean ± SD. Whereas AUC = ∫096 Cpdt, Cp was
plasma concentration at time t.
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Statistical Analysis
The presented results are shown as the mean ± SD. All data were processed and
graphed with Microsoft Excel 2003 (Redmond, WA). Data analysis was performed with
the statistical software SigmaStat for Windows (Version 1.0, Jandal Corporation, San
Rafael, CA). One-way ANOVA was employed to examine significant differences at
P < 0.05.

RESULTS
Effects of Tetracycline and Dieldrin on Pgp Transport
The effect of tetracycline on Pgp transport activity was evaluated using in situ
prepared, isolated perfused catfish liver preparation. The cumulative excretion of Rho123 (nM/kg body weight) into bile during 210 min isolated liver perfusions of 1 µM Rho123 is presented in figure 2.2. In the presence of 20 µM tetracycline, the cumulative
biliary accumulation of Rho-123 (10.65 ± 2.45 nM/kg body weight) over 210 min was
significantly less than that transported into bile by control livers (19.29 ± 5 nM/kg body
weight) (p < 0.008). Tetracycline treatment resulted in a 45% decrease in biliary
accumulation, as compared with Rho-123 alone.
Similar to tetracycline, dieldrin decreased Rho-123 transport into bile in isolated
perfused livers (Fig. 2.3). In the presence of 20 µM dieldrin, biliary accumulation of Rho123 during the 210 min liver perfusion was significantly lower (40%) than controls (p <
0.011), with 210 min cumulative control and treatment values of 11.5 ± 1.75 nM/kg body
weight and 6.80 ± 3.01 nM/kg body weight, respectively.
Effects of Verapamil on Biliary Excretion of [3H]-TET
The contribution of Pgp in the transport of [3H]-TET into bile was examined
using verapamil, a competitive inhibitor of Pgp, in the isolated perfused liver
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Figure 2.2 - Transport of Rho-123 into bile from isolated perfused catfish livers
exposed 210 min to 1 µM Rho-123 with vehicle control or tetracycline (20 µM). Each
column represents mean ± SD (nM Rho-123/kg body weight) for controls (n = 6) and
tetracycline treatments (n = 5). * = Significantly different from controls at p < 0.05.
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Figure 2.3 - Transport of Rho-123 into bile from isolated perfused catfish livers
exposed 210 min to 1 µM Rho-123 with vehicle control or dieldrin (20 µM). Each
column represents mean ± SD (nM Rho-123/kg body weight) for controls (n = 5) and
dieldrin treatments (TRT) (n = 7). * = Significantly different from controls at p <
0.05.
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Cumulative Excretion of [3H]-TET
in Bile (pM/kg per body weight)
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Figure 2.4 - Transport of [3H]-tetracycline (TET) into bile from isolated perfused
catfish livers during 210 min exposure to 8.8 nM [3H]-TET with vehicle control or
verapamil (VER) (20 µM). [3H]-TET equivalents transported into bile, expressed as
pM/kg body weight. Each time point represents mean ± S.D. for controls (CTR) (n = 6)
and VER treatments (TRT) (n = 5) (CTR: [3H]-TET; TRT: [3H]-TET + VER). * =
Significantly different from controls at p < 0.05.
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preparations. Biliary accumulation of [3H]-TET equivalents (pM/kg body weight) from
isolated perfused livers during exposure to 8.8 nM [3H]-TET with vehicle alone or
verapamil (20 µM) is shown in figure 2.4. As compared with [3H]-TET alone, the amount
of [3H]-TET equivalents transported into bile during verapamil treatment was lower at all
time points. These differences increased over time, with significant differences evident
between the two treatments at the 150, 180 and 210 min samplings (Control: 68.29 ±
23.69; TRT: 40.35 ± 5.8) (p < 0.05). At 210 min, bile accumulation of [3H]-TET
equivalents in the presence of 20 µM verapamil (89.88 ± 7.5) was 34% lower than that
with 3H-TET alone (135.29 ± 37.8) (p < 0.024).
Effects of Dieldrin on Biliary Excretion of [3H]-TET
Following a similar protocol, the effect of dieldrin on biliary excretion of [3H]TET was examined. Cumulative [3H]-TET equivalent transport into bile (pM/kg body
weight) over time is presented with or without dieldrin (20 µM) (Fig. 2.5). As compared
with vehicle alone (104.37 ± 16.96), the cumulative [3H]-TET equivalent content in bile
during 210 min dieldrin treatment (50.43 ± 8.99) was significantly lower (p < 0.002).
Not only was there an overall inhibitory effect on transport of [3H]-TET, but the rate of
transport into bile was also reduced by dieldrin treatment. By 120 min, the amount of
[3H]-TET equivalents transferred into bile during dieldrin treatment (6.69 ± 2.28) were
significantly different from that with [3H]-TET alone (16.6 ± 9.20) (p < 0.05). These
differences increased over time. At 210 min, dieldrin treatment resulted in a nearly 50%
decrease in biliary excretion of [3H]-TET equivalents, a much greater decrease than
observed with verapamil (34%).
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Figure 2.5 – [3H]-tetracycline (TET) equivalents transported into bile from isolated
perfused catfish livers during 210 min exposure to 8.8 nM [3H]-TET with vehicle
control or dieldrin (20 µM). Data are expressed as pM [3H]-TET equivalents/kg body
weight and each time point represents mean ± SD for controls (CTR) (n = 5) and
dieldrin treatments (TRT) (n = 5) (CTR: [3H]-TET; TRT: [3H]-TET + DIELDRIN). * =
Significantly different from controls at p < 0.05.
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Effects of Dieldrin Pretreatment on In Vivo Pharmacokinetics of [3H]-TET
Experiments were conducted to investigate the effects of dieldrin pretreatment
(0.1 mg/kg body weight per day for 28 days) on the pharmacokinetics of a single
intravascular dose of [3H]-TET (20 µCi/kg or 8.31 µg/kg body weight) (Fig. 2.6). Lower
plasma concentrations of [3H]-TET equivalents were observed at all time points after
dose administration in dieldrin-pretreated fish, as compared to the controls. Significant
differences were detected 72 h to 96 h (p < 0.05) (Fig. 2.6). Pharmacokinetic parameter
values as determined by the two compartment model for administration of a single
intravascular dose appear in Table 2.1. The values obtained for AUC0-96 were
significantly lower 27% in dieldrin treated fish (166.52 ± 26.98 h*ng/ml) than in the
control animals (227.27 ± 50.81 h*ng/ml) (p < 0.05). Consistent with the decreased
AUC0-96, the value of the plasma clearance of [3H]-tetracycline in dieldrin pretreated fish
(42.12 ± 6.82 ml/h) was elevated by 17% compared to that in controls (31.64 ± 6.21
ml/h) (p < 0.035).

Significant differences were not observed for the half life of

elimination (t1/2 kel) between two groups.
Tissue Distribution and Mass Balance of [3H]-TET
[3H]-TET molar equivalents were widely distributed to most tissues of the catfish
after the intravascular administration in both control and dieldrin treated groups (Table
2.2). The highest concentrations of [3H]-TET equivalents were found in the bile, liver,
kidneys and intestine. Concentrations of [3H]-TET equivalents in liver, kidneys, fat and
eggs were significantly decreased at 72h post administration in the dieldrin pretreatment
catfish, as compared to controls (p < 0.05). When mass balanced, the percentage of the
administrated dose among all tissues at 72 h post dose is in Table 2.2. Chronic dieldrin
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Figure 2.6 - Mean plasma [3H]-Tetracycline (TET) equivalent concentrations following
a single intravascular administration of [3H]-TET at 20 µCi/kg body weight (8.31
µg/kg) to catfish pretreated 4 weeks to a diet containing vehicle control (CTR) or
dieldrin (0.1 mg/kg body weight per day) (TRT). Data are plotted upon a
semilogarithmic scale and each concentration time point represents mean + SD (ng/ml)
of five or six measurements (CTR: [3H]-TET; TRT: [3H]-TET + DIELDRIN). * =
Significantly different from controls at p < 0.05.
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Table 2.1 - The values of Pharmacokinetic parameters obtained from two
compartment analysis after a single intravascular dose of [3H]-tetracycline
(TET) at 20 µCi/kg body weight (8.31 µg/kg) to channel catfish exposed 4
weeks to a diet containing vehicle control or dieldrin (0.1 mg/kg body weight
per day) (CTR without dieldrin exposure; TRT with dieldrin exposure).

Value

Parameter

CTR

TRT

Alpha (α) (h-1)

0.587 ± 0.332

0.505 ± 0.233

Beta (β) (h-1)
A (ng/ml)
B (ng/ml)

0.026 ± 0.002
4.200 ± 0.667
1.214 ± 0.479

0.031 ± 0.005
3.555 ± 0.370
0.981 ± 0.171

t1/2(α) (h)

1.474 ± 0.697

1.632 ± 0.730

t1/2(β) (h)

26.999 ± 2.494

22.812 ± 3.925

kel (h-1)

0.099 ± 0.003

0.116 ± 0.026

k12 (h-1)

0.355 ± 0.232

0.285 ± 0.160

k21 (h-1)

0.158 ± 0.103

0.135 ± 0.057

t1/2 kel (h)

7.000 ± 0.188

6.214 ± 1.349

227.27 ± 50.81
381 ± 67
22.465 ± 4.689
31.64 ± 6.21

*166.52 ± 26.98
445 ± 44
18.823 ± 2.013
*42.12 ± 6.82

AUC (h*ng/ml)
Volume (ml/kg)
Cmax (ng/ml)
Clearance (ml/h)

† The values of parameters are the mean ± SD of five or six measurements.
† t1/2(α), half-life of [3H]-TET in plasma during distribution phase; t1/2(β), halflife of elimination phase; t1/2 kel , half-life of elimination; AUC, the area
under plasma concentration time curve; Volume, volume of distribution;
Clearance, the total plasma clearance. *= Significant difference from
controls (p<0.05).
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Table 2.2 - Tissue concentrations and distribution of [3H]-tetracycline (TET)
equivalents at 72h following a single intravascular administration of [3H]-TET at
20 µCi/kg body weight (8.31 µg/kg) to channel catfish exposed 4 weeks to a diet
with or without dieldrin (0.1 mg/kg body weight per day) (CTR without dieldrin
exposure; TRT with dieldrin exposure).

Tissue/Bile
Bile
Liver
Spleen
Kidney
Heart
Intestine
Stomach
Fat
Gill
Muscle
Eggs

Concentration
ng/kg

% of Dose

CTR

TRT

CTR

TRT

1010.27 ± 883.1

905.94 ± 454.7

9.946 ± 5.741

11.048 ± 4.840

*3.19 ± 0.6

0.673 ± 0.142

0.554 ± 0.113

4.44 ± 1.10
1.30 ± 0.87

1.37 ± 0.64

0.012 ± 0.006

0.013 ± 0.007

4.85 ± 0.45

*3.83 ± 0.31

0.325 ± 0.028

*0.265 ± 0.031

1.75 ± 0.30

1.61 ± 0.42

0.012 ± 0.002

0.012 ± 0.003

3.33 ± 0.87

3.76 ± 1.34

0.331 ± 0.165

0.383 ± 0.102

1.41 ± 0.28

1.10 ± 0.37

0.145 ± 0.020

0.113 ± 0.034

1.48 ± 0.05

*1.14 ± 0.17

0.028 ± 0.023

0.017 ± 0.010

1.14 ± 0.17

1.04 ± 0.25

0.207 ± 0.013

0.195 ± 0.052

0.90 ± 0.33

0.66 ± 0.13

3.933 ± 1.389

2.979 ± 0.563

0.91 ± 0.22

*0.45 ± 0.08

1.505 ± 0.706

0.611 ± 0.338

Tissue
Accumulation

7.171 ± 1.855

*5.1.42 ± 0.803

Total
Accumulation

17.117 ± 6.14

16.190 ± 5.44

† Tissue accumulation is the sum of distributions of [3H]-TET equivalents in all
tissues, including liver, spleen, kidneys, heart, intestine, stomach, fat, gill,
muscle and eggs, whereas total accumulation consists of tissue accumulation
and bile distribution.
† Muscle compartment was assumed to be 50% of carcass in catfish (Bosworth
et al., 2001).
† Values are expressed as ng [3H]-TET equivalents/kg and data represents mean
± SD. of five or six measurements. * =Significant difference from controls
(p<0.05).
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pretreatment resulted in a trend for increased accumulation of [3H]-TET equivalents in
bile as percent of dose, but no statistical difference was detected between controls and
treated group due to the high variability among fish. In contrast, the total accumulation of
[3H]-TET equivalents as percent of dose in pretreated catfish tissues (5.142 ± 0.803),
including liver, spleen, kidneys, heart, intestine, stomach, fat, gill, muscle and eggs, was
significantly less (28%) than that in controls (7.171 ± 1.855) (p < 0.037). In the kidneys,
distribution of [3H]-TET equivalents was significantly reduced 19% by dieldrin
pretreatment (p < 0.008).
Hepatic Pgp Expression
Pgp expression in hepatic plasma membranes from catfish following 4-week
dietary exposure to vehicle control or dieldrin (0.1 mg/kg body weight per day) was
measured. A 170 kDa C219 immunoreactive protein was observed in liver membrane
preparations in both control and dieldrin treated fish (Fig. 2.7.B). Following dieldrin
treatment, the level of staining density of immunoreactive Pgp in hepatic plasma
membrane was significantly increased by 23%, as compared to that in controls (p <
0.037) (Fig. 2.7.A).

DISCUSSION
The isolated perfused liver Rho-123/tetracycline and tetracycline/verapamil
comparisons presented in these studies suggest that tetracycline is transported by Pgp or
at least interacts with Pgp substrates. Tetracycline has been shown to be a substrate of
Pgp homologues in bacteria and in cultured mammalian cells, however, there have been
few comparative studies performed in the whole animal or perfused organs.
Investigations performed in bacteria have demonstrated that multidrug resistance (MDR)
and gene tranfections of Pgp homologues reduced intracellular accumulation of
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Figure 2.7 – A. Levels of C219 immunoreactive Pgp in the hepatic plasma membrane
from catfish following 4-week dietary exposure containing vehicle control or dieldrin
(0.1 mg/kg body weight per day). Data are expressed as relative staining intensity of
antibody immuoreactivity for Pgp protein following standardization for inter-gel
variability. Each column represents mean ± SD of five or six measurements. * =
Significantly different from controls at p < 0.05. B. Western blot of Pgp protein in
hepatic plasma membrane proteins in control or dieldrin pretreated fish. S = Pgp protein
internal standard.
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tetracycline, as compared to non-transfected bacteria (Levy, 1992; George et al., 1996;
Chollet et al., 2004; Qin et al., 2004). Furthermore, cyclosporin A and verapamil, both
competitive inhibitors of Pgp, completely reversed tetracycline resistance and increased
accumulation of tetracycline in two human leukemic cell lines expressing Pgp (Kavallaris
et al., 1993). These in vitro findings are consistent with the concept that tetracycline is a
substrate of Pgp. Many prototypic substrates of Pgp, such as Vinca alkaloids,
anthracyclines, epiodophyllotoxins, rhodamine dyes and doxorubicin share a ring
structure similar to the four-ringed structure of the amphiphilic tetracycline (Fig. 2.1)
(Argast and Beck, 1984; Lampidis et al., 1989; Germann et al., 1996; Sharom, 1997;
Mealey et al., 2002). This structure and tetracycline’s physical properties appear to
enhance partitioning into the cell membrane and the active interaction with Pgp (Bain et
al., 1997). The transport mechanism which allows this broad substrate specificity has not
been clearly defined. Pgp substrates, however, appear to share several common
characteristics, including moderate hydrophobicity, amphiphilicity, low molecular
weight, and a complex ring structure (Lampidis et al., 1989; Germann et al., 1996; Bain
et al., 1997). Pgp substrates have been shown to gain access to the binding site(s) of the
Pgp transporter from the inner leaflet of lipid bilayer of the plasma membranes and
interact with Pgp within the membrane rather than in the aqueous phase (Raviv et al.,
1990; Higgins and Gottesman, 1992; Sharom, 1997; Romsicki and Sharom, 1999).
Tetracycline (20 µM) resulted in a 45% decrease in transport of Rho-123, a
prototypic substrate of Pgp (Fig. 2.2), and verapamil (20 µM), a substrate and
competitive inhibitor of Pgp, decreased the amount of [3H]-tetracycline transported into
bile by 34% (Fig. 2.4) (Spoelstra et al., 1994; Saeki et al., 1993; Tsuji et al., 1993; Didier
et al, 1995; Maki et al., 2003), during the 210 min isolated liver perfusions. Transport
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studies suggest that inhibition of Pgp could result either from the competition of
substrates at binding sites, from allosterical interactions by simultaneous binding to Pgp
at different sites, or from blockage of ATP binding and hydrolysis process (Ford, 1996;
Tamai and Safa, 1991; Ramachandra et al., 1998; Senior et al., 1995). Like other classic
competitive inhibitors, verapamil has been developed as an inhibitor to identify the
potential for drug-drug interactions due to Pgp (Keogh and Kunta, 2006). In the current
study, verapamil was employed as an inhibitor to examine the contribution of Pgp to
excretion of [3H]-tetracycline into bile. Taking into consideration the limited duration of
exposure, the appreciable decrease in [3H]-tetracycline equivalent movement into bile,
these results suggest that Pgp transport plays a significant role for biliary excretion of
[3H]-tetracycline. These findings are consistent with the concept that tetracycline acts as a
substrate, a competitive inhibitor or by altering Rho-123 binding/transport by interacting
at another site. While the exact mechanism is unknown, tetracycline appears to interact
with Pgp transport.
Interactions of xenobiotics with Pgp are complex. A number of organochlorine
compounds, including DDT, DDD and DDE, when dosing occurs at 20 µM have been
shown to reduce the efflux transport of the prototypic Pgp substrate Rhodamine B (1 µM)
from the gills in the marine mussel M. galloprovinvialis (Galgani et al., 1996). Similarly,
the current study, when using dieldrin (20µM), another highly hydrophobic
organochlorine, observed decreased transport of Rho-123. In this case, transport of Rho123 (1 µM) into bile from isolated perfused livers was decreased 40% (Fig. 2.3). Other
studies, however, have been obtained in vitro (using murine melanoma cell lines
expressing human MDR1 gene) where the intracellular accumulation of the Pgp
substrate, doxorubicin (50 µM), was not affected by DDT, DDE and dieldrin (100 µM)
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(Bain and Leblanc, 1996). The inconsistency in response to these organochlorine
compounds could be related to the different organchlorine concentrations, concentrations
of Pgp substrates used to detect Pgp inhibition, or the duration of exposure.
Several studies have demonstrated that dieldrin inhibits the ATPase system
involved with Mg2+, Ca2+, Na+-K+ pumps on the plasma membrane in the fish and rabbit
(Akera et al., 1971; Desaiah and Koch, 1975; Bandyopadhyay et al., 1982; Mehrotra et
al., 1988). As an ATPase inhibitor, the inhibitory action of dieldrin upon Pgp transport of
Rho-123 and [3H]-tetracycline in the current study may result from the reduction of
ATPase activity. Other studies have reported that ATPase inhibitors, including the
flavonoid quercetin and 5,7,3′,4′,5′-pentamethoxyflavone (PMF), inhibited Pgp transport
by interfering with the basal and substrate-stimulated ATPase activity (Shapiro and Ling,
1997; Choi et al., 2004). Therefore, dieldrin may alter ATPase system on the plasma
membrane (Verma et al., 1978) and hence block the active transport of Pgp substrates
through the cell membrane as a noncompetitive inhibitor.
As seen with substrate-metabolizing enzymes, efflux transport activity of Pgp on
the cell membrane may be saturated at elevated Pgp substrate concentrations (Lin, 2003).
In contrast, the influx of these compounds into the cell by diffusion would not exhibit
concentration based limitations other than those already imposed by the physiochemical
characteristics of the compound and the membrane. In this situation, as the substrate
concentration increases, the impact of Pgp efflux on intracellular accumulation is
quantitatively less important (Lin, 2003). To explain these discrepancies, it is plausible
that even though Pgp inhibition occurs at lower concentrations, it may not significantly
affect the intracellular accumulation of this Pgp substrate at higher concentrations. This
phenomenon may contribute to the apparent dichotomy between [3H]-tetracycline
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disposition at high dieldrin doses used in the perfusion studies (inhibit movement into
bile) and the latter chronic dieldrin exposures which facilitated [3H]-tetracycline
elimination.
Alternatively, different findings may result from the use of different species, cell
lines, ectera between the current and past studies. Contrasting results were observed with
in vitro studies in mussel gills examining DDT, DDD and DDE, and polychlorinated
biphenyl--Aroclor 1254 as inhibitors for Pgp transport. These compounds acted as
inhibitors in one species of mussel (Mytilus galloprovincialis) (Galgani et al., 1996), but
did not appear to affect Pgp transport activity in another species (Mytilus californianus)
(Cornwall et al., 1995). A difference in the size of the Pgp-like protein reacting to C219
monoclonal antibody in these two species was observed (Galgani et al., 1996). It remains
to be clarified whether such disagreement results from concentration, species or other
experimental differences.
The foregoing studies suggest that tetracycline is transported by Pgp and dieldrin
may influence Pgp transport activity. Acute high dose dieldrin exposures resulted in
marked inhibitory effects on the biliary excretion of [3H]-tetracycline equivalents.
Tetracycline equivalent transport was decreased by dieldrin (50%) to a greater extent than
observed for verapamil (34%). In addition, a significant decline in transport was achieved
earlier during dieldrin treatment than with verapamil. These results suggest that dieldrin
acts as a more potent inhibitor of Pgp than verapamil. Inhibition of Pgp by dieldrin
slowed down clearance of tetracycline from the liver into bile and prolonged intracellular
residence time of tetracycline in the liver. Since biliary excretion is an important pathway
for the elimination of tetracyclines out of fish (Plakas et al., 1988), these results would
suggest that dieldrin co-exposure would result in decreased transport of tetracycline into
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bile, and perhaps decreased clearance from the animal. Unpredictably and in contrast to
the inhibitory effects of dieldrin (20 µM) on transport of [3H]-tetracycline into bile,
chronic dieldrin pretreatment resulted in significantly lower mean plasma concentrations
at 72 h and 96 h post administration (Fig. 2.6), a 27% decrease in the AUC0- 96h, and a
17% increase in the plasma clearance of a single and subsequent dose of [3H]tetracycline, as compared to controls (Table 2.1). These alterations were coincided with a
23% increase in hepatic Pgp expression in dieldrin treated fish (Fig. 2.7), which may
contribute to the enhanced clearance and elimination of [3H]-tetracycline equivalents.
Regulation of Pgp expression in response to inducers has been extensively studied in
vitro and in vivo (Kliewer et al., 1998; Moore et al., 2000; Staudinger et al., 2001;
Mikamo et al., 2003). DDE has been shown to increase expression of Pgp in the gill
tissues of the mussel Mytilus californianus (Eufemia and Epel, 2000). Induction of Pgp
by dieldrin treatment as seen in the current in vivo studies with catfish would be
consistent with literature findings.
Previous studies showed that chronic dieldrin exposure stimulated biliary
excretion of [14C]-dieldrin, [3H]-DMBA and [14C]-BaP in rainbow trout (Gilroy et al.,
1993; Donohoe et al., 1998; Barnhill et al., 2003), and an apparent increase of Pgprelated immunoreactivity in liver sections as detected by the C94 monoclonal antibody.
The C219 and JSB-1 anti Pgp monoclonals, however, did not show similar differences
(Curtis et al., 2000). Differences in sensitivity and specificity of antibodies reacting to the
Pgp protein may have contributed to these observed inconsistencies in Pgp-related
responses in the rainbow trout liver. The current study showed a significant induction of
hepatic C219 reactivity in catfish following comparable dietary dieldrin treatment. The
disparity in Pgp-related responses between the current study and the previous Curtis
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study (Curtis et al., 2000) may be attributed to species differences in response to the Pgp
inducer (Lin, 2003). Cytotoxic drugs, including adriamycin, daunomycin and
mitoxantrone, and the polycyclic aromatic hydrocarbon, 3-MC, induced expression of the
MDR gene in rat and mouse hepatocytes, with little inductive effect on human cells
(Fardel et al., 1996; Chin et al., 1993). The activation of Pgp also occurs at the posttranslational level. Studies have shown that phosphorylation of serines and threonines on
Pgp protein increased drug resistance activities in mammalian cell lines (Ratnasinghe et
al., 1998). The activation of Pgp at the post-translational level is expected to elevate the
transport ability of Pgp rather than expression of the MDR gene (quantity of Pgp protein).
As an inducer of Pgp, dieldrin may involve different mechanisms to regulate expression
of Pgp and activation of Pgp in different species (fish). While these mechanisms are
possibilities, it remains to be clarified whether such disagreements result from dosage,
detection methods, the length of xenobiotics exposure, experimental conditions, or other
experimental differences (Doi et al., 2001).
Mechanisms by which dieldrin exposure altered the pharmacokinetics of
tetracycline may include not only induction of Pgp, but also by changes in the
biotransformational enzymes, especially CYP450s. Several studies have demonstrated
that dieldrin activated PXR and the constitutive androstane receptor (CAR) in mammals
to induce CYP3A and CYP2B family enzymes (Coumoul et al., 2002; Wei et al., 2002;
Lemaire et al., 2004). However, in rainbow trout, the increased biliary excretion of [14C]dieldrin, [3H]-DMBA and [14C]-BaP following chronic dieldrin treatment was not
correlated to enzyme induction (Gilroy et al., 1993; Donohoe et al., 1998; Barnhill et al.,
2003). No significant differences in total hepatic CYP450s, glutathione S-transferase,
UDP glucuronosyltransferase and sulfotransferase activities were evident with dieldrin
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exposure (Gilroy et al., 1993; Barnhill et al., 2003). Immunoblot analysis also revealed no
change in expression of hepatic CYP isozymes (Gilroy et al., 1996). In addition, the
biliary metabolite profile of [14C]-BaP was not significantly altered following dieldrin
exposure in vivo (Barnhill et al., 2003). These findings suggest that induction of
metabolizing enzymes by dieldrin treatment is unlikely in fish. On the other side,
tetracycline undergoes minimal metabolism and is not biotransformed to a significant
extent in animals (Aronson, 1980). Therefore, induction of Pgp may well be the most
important factor in alterations of the pharmacokinetics of [3H]-tetracycline in the current
study. These studies support the concept that Pgp induction contributed to these
alterations.
Following a single intravascular dose of [3H]-tetracycline (20µCi/kg; 8.31µg/kg),
tetracycline molar equivalents (parent and metabolites) were widely distributed to most
tissues with the highest concentrations in the intestinal, hepatic and renal tissues of both
control and dieldrin treated catfish (Table 2.2). These findings are comparable to previous
studies with tetracycline (Plakas et al., 1988). Dieldrin has been shown to be readily
absorbed and accumulate in liver, kidney, bone marrow and adipose tissues in the body of
fish (Jorgenson, 2001). As dieldrin inhibited Pgp transport of [3H]-tetracycline into bile in
the isolated perfused liver, dieldrin would be expected to inhibit Pgp transport of [3H]tetracycline in tissues of mutual distributions. However, concentrations of dieldrin in
these tissues may be too low to inhibit Pgp transport activity in the current chronic
exposure study. In a previous study, a concentration of only about 1.8 nM (~ 0.7 ug/g
tissues) of dieldin was achieved in the liver after dietary exposure to dieldrin at 0.324
mg/kg body weight daily for six weeks in rainbow trout (Barnhill et al., 2003). Although
a different species was used in the current study, a lower dosage (0.1 mg/kg body weight
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per day) and a shorter exposure period (4 weeks) may have resulted in a lower
concentration of dieldrin in the liver of exposed catfish. At such a concentration, dieldrin
may not have resulted in significant inhibitory effects on Pgp transport since Pgp
inhibition is concentration-dependent (Lin, 2003). Even though Pgp inhibition by dieldrin
may have occurred in the chronic dieldrin exposed fish, the inhibition would be much
smaller than that observed in the isolated perfused liver. The Pgp inductive effect
following chronic dieldrin exposure would mask these inhibitory effects.
Pgp is constitutively located on the bile canalicular membrane of hepatocytes, the
brush-border epithelial cells of the intestine, and the luminal side of renal proximal
tubules (Cordon-Cardo et al., 1990; Schinkel et al., 1996; Balayssac et al., 2005;).
Induction of Pgp may alter tissue distributions and excretion of Pgp substrates (Table
2.2). Consistent with previous findings in the rainbow trout studies, dieldrin pretreatment
resulted in greater excretion of [3H]-tetracycline equivalents in bile at 72 h after dosing
with a single administration. However, significant differences from the controls were
probably hid by large variability among fish. In addition, the inductive effects of Pgp may
also occur in the kidneys as well as intestine, leading elevated excretion of [3H]tetracycline into urine and the intestinal lumen. Compatible to increased excretion of
[3H]-tetracycline, the total accumulation of [3H]-tetracycline in pretreated catfish tissues,
including liver, spleen, kidneys, heart, intestine, stomach, fat, gill, muscle and eggs, was
significantly lower than that in controls, perhaps as a cumulative effect of Pgp induction.
In current study, chronic dieldrin led to a decrease in tissue concentrations and
systemic exposure of tetracycline in fish. Drug-drug interactions with Pgp induction are
of concern for attenuated therapeutic effects of drugs in clinical treatment (Lin, 2003). In
the aquatic environment, fish may be constantly exposed to various contaminants
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including dieldrin-like compounds and Pgp induction may occur in response to the
contaminant body burdens (Bard, 2000). Few studies exist regarding influence of
environmental contaminants on therapeutic effects of drugs in fish or the involvement of
Pgp induction. The current study provides information that suggests chronic contaminant
exposure may be a determinant factor for therapeutic effects of drugs used in fish.
In summary, this study provides results consistent with tetracycline as a substrate
of Pgp and a competitive inhibitor of Rho-123 transport into bile of the isolated perfused
liver of catfish. In addition, dieldrin inhibited biliary transport of Rho-123 and
tetracycline. In contrast, chronic dieldrin exposure resulted in increased elimination of
[3H]-tetracycline, as evidenced by a decrease in AUC, reduced tissue concentrations, and
an increase in the whole body clearance. In dieldrin treated fish, induction of Pgp in
hepatic plasma membranes may be responsible for alterations of the pharmacokinetics
and disposition of [3H]-tetracycline. Cumulatively, these results suggest dieldrin has the
potential to inhibit Pgp transport of tetracycline at the high concentrations with an
inductive effect upon Pgp expression predominating at the low concentration chronic
exposures in vivo. Dieldrin co-exposure would result in altered disposition of
tetracycline, leading to toxicities and potential misdosing; whereas multidrug resistance
may follow induction following chronic dieldrin exposure.
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CHAPTER 3: ENHANCED BIOACCUMULATION OF
IVERMECTIN AND BENZO[A]PYRENE IN CATFISH BY
EXPOSURE TO THE SURFACTANT C18 LINEAR
ALKYLBENZENE SULFONATE
INTRODUCTION
Fish are widely consumed by humans as a healthy low fat, protein rich,
micronutrient and omega-3 (n - 3) fatty acid enhanced food (Daviglus et al., 2002). Over
the past several decades a large number of studies suggest that fish effectively
bioaccumulate and in some cases biomagnify select contaminants from the environment
(Bryan, 1979; Clarkson, 1995). Consumption advisories have been issued for eating fish
from impacted waters and for specific species of fish occupying higher trophic niches
[U.S. Environmental Protection Agency (EPA) 2004]. Compounds such as mercury,
polychlorinated biphenyls (PCB), DDT, and polycyclic aromatic hydrocarbons (PAHs)
have received much of this attention. Recently the list of compounds which may enter the
human food chain via fish has been expanded to include a variety of pharmaceuticals
(Hastein et al., 2006). Drugs have entered waterways and fish by aquaculture practices,
runoff from concentrated animals feeding operations and municipal sources (Daughton
and Ternes, 1999).
The risk of contaminants in the aquatic environment to the fish consuming public
is dependent on the uptake or bioavailability of contaminants to the fish, the
bioaccumulation of contaminants in the fish to be consumed and the bioavailability of the
contaminants from a fish meal to the human consumer. A variety of factors are known to
influence bioavailability and bioaccumulation of contaminants in fish (Leblanc, 1995;
Ivanciuc et al., 2006). Notably, compound exposure, lipophilicity and the susceptibility of
the chemical to biotransformation, play an important role in dictating contaminant body
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burdens. Recently, studies in mammals suggest that Phase III transport processes by ABC
transporter such as P-glycoprotein (Pgp) and multidrug resistance-related proteins (Mrp)
have a significant effect on drug bioavailability from the intestine (Kurata et al ., 2002;
Liu and Hu, 2000; Fromm, 2000) and in compound elimination from the body (Shitara,
2006). Likewise, fish have been shown to have ABC “like” efflux transporters in
excretory pathways as well as routes of bioavailability such as the intestinal mucosa
suggesting similar roles of these “like” transporters in compound disposition and
bioavailability.
Contaminants found in the aquatic environment often exist as mixtures with other
compounds (Yang et al., 1998). The interactions of components in mixtures have been
shown to result in synergistic, antagonistic or additive effects on aquatic organisms
(Altenburger et al. 2003). Surfactants, common environmental pollutants and mixture
components in aquatic systems (Ahel et al., 1993; Todorov et al., 2002), generally exhibit
a low order of direct toxicity to aquatic organisms; however, several studies are
suggestive of interactive effects of surfactants upon the bioavailability and disposition of
other compounds (Mann, 1962; Solon, et al., 1969; Pärt et al., 1985). Studies examining
strategies to inhibit the involvement of ABC transporters in cancer multidrug resistance
have examined surfactants as a means to inhibit Pgp and Mrp’s contribution to this
phenomenon (Kabanov et al., 2002). Initial indications suggest that surfactants may
enhance membrane permeability (Drori et al., 1995; Hendrich and Michalak, 2003) or
inhibit transporter efflux action directly (Woodcock et al., 1992; Nerurkar et al., 1996;
Miller et al., 1999; Regev et al., 1999; Alqawi and Georges, 2003). These activities may
increase effective chemotherapeutic levels in cancer cells.
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This study addresses experimentally two hypotheses. First, is that the C18 linear
alkylbenzene sulfonate (LAS) surfactant at environmental concentrations can inhibit the
efflux activity of Pgp “like” transporters in the bile canniculi of the catfish liver. A
second hypothesis is that the C18 LAS surfactant at environmental levels, through its
action on Pgp and/or membrane permeability, can influence xenobiotic bioavailability or
bioaccumulation. The widely used veterinary pharmaceutical ivermectin and the PAH
and environmental contaminant benzo[a]pyrene (BaP) were selected as model
compounds based on their possible involvement with ABC transporters, environmental
relevance and their limited bioaccumulation.

MATERIALS AND METHODS
Chemicals
3

H-Ivermectin (IVM) was purchased from American Radiolabeled Chemicals,

INC., St Louis, MO. 3H-Benzo[a]pyrene (BaP) was obtained from GE Healthcare UK
Limited Amersham Place Little Chalfont Buckinghamshire HP79 NA, UK and BaP from
Midwest Research Institute, Kansas City, MO. Methylene blue was obtained from Fisher
Scientific Company, Fair Lawn, NJ. Tricane methane sulfonate (MS-222) was provided
by Argent Chemical Company, Redmond, WA. Heparin sodium (1000 USP units/ml)
was acquired from Elkins-sinn, Inc., Cherry Hill, NJ. Sodium dodecylbenzenesulfonate
(C18 LAS) (~80%), rhodamine-123 (Rho-123), ivermectin (IVM), sodium tetraborate,
chloroform, and all other chemicals used for buffer preparations were supplied by Sigma,
St Louis, MO.
Animals
Channel catfish, Ictalurus punctatus, were obtained from the Louisiana State
University Aquaculture Research Station, Baton Rouge, LA, USA. Animals were grown
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and maintained under a 12 h light/dark photoperiod in laboratory tank supplied with
flow-through tap water. Water was dechlorinated and maintained at ~18oC. All fish were
acclimated for one month prior to use in the experiment.
In Situ Hepatic Rho-123 Disposition Studies
Surgical Procedure
Catfish of both sexes were fasted 24 h prior to surgery. The surgical preparation
and perfusion of isolated livers were performed as previously described (Kleinow et al.,
2004). Animals were anesthetized with MS-222 at induction and maintenance doses of
106 and 86 mg/l, respectively. The liver, gall bladder and hepatic portal vein were
exposed by the ventral midline and transverse incisions posterior to the pectoral girdle.
Following collection of residual bile and ligation of common bile duct, the gall bladder
was cannulated in the apex with a PE260 tubing for subsequent bile collections. The
portal vein and collateral vessels afferent to the liver were isolated, and ligatures were
loosely placed around each. The portal vein was cannulated using a Quick-cath 14G
cannula filled with heparin anticoagulant. Once ligated in place, oxygenated and
heparinized (10 USP/ml) teleost Ringer's solution (117.2 mM NaCl, 4.8 mM KCl, 0.9
mM CaCl2, 1.5 mM MgSO4, 12.3 mM Na2HPO4, 1.4 mM NaH2PO4, 5 mM glucose, pH
7.4) was continuously perfused into the afferent cannula. Collateral vessels were rapidly
tied off, and the efferent hepatic vein was cut at the level of the cardinal sinus to establish
flow through the liver. Upon completion of perfusion circuit, the liver was transiently
blanched, removed from the animal and placed on a perforated platform of a temperature
controlled recirculation perfusion apparatus. Head pressure was maintained at 12 cm to
create physiological pressures for media perfusion during the experiment. Livers were
pre-perfused with oxygenated teleost Ringer’s solution (1L) containing vehicle alone for
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control or individual treatments at temperatures dictated by the individual experiments.
This process removed remaining blood and preexposed livers to specific treatment
conditions.
Isolated Liver Perfusion of Rho-123
To examine the influence of LAS on hepatic disposition of the Pgp prototypic
substrate Rho-123, six groups of five fish (1999.5 ± 447.9 g) were prepared for the in situ
isolated liver perfusions. The six treatments included control, three LAS treatments (1, 5,
and 20 μM) maintained at 18 °C, and two additional controls perfused at 23 °C and 28
°C, respectively. The 23 °C and 28 °C experiments served as positive controls for
changes in fluidity. Following pre-perfusion, livers were perfused in a recirculating
system for 210 min with 250 ml of media, which were thermally and compositionally
identical to the pre-perfusion mixture, except containing 1 μM Rho-123. Samples of bile
and perfusate were collected at 30 min intervals for 210 min for fluorometric analysis.
Once liver perfusions were completed, the liver was removed and weighed. Two
aliquots of liver were snap frozen in liquid nitrogen and stored at -80 °C in the phosphate
buffer for extraction of Rho-123 (see below) and in the buffer A for membrane fluidity
studies (see below), respectively.
Extraction of Rho-123
To determine the amount of Rho-123 remaining in liver after in situ isolated liver
perfusions, Rho-123 extraction was performed according to the published methods
(Sweatman et al., 1987). The liver tissue for each fish was blotted dry, weighed, and
homogenized in 2 volumes of ice-cold phosphate buffer (100 mM Na2HPO4 and
NaH2PO4, pH 8.5). A 3-mL aliquot of the homogenate was transferred into a siliconecoated and capped tube prior to incubation at 4 oC for 30 min. Samples were extracted 3
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times with 7 ml of freshly prepared ethyl acetate:1-butanol (9:1, v/v) and centrifuged
each time at 510xg (IEC Centra CL3 Centrifuge) for 3.5 min. Organic phases of Rho-123
extraction were combined in silicone-coated tubes, evaporated to dryness under a stream
of nitrogen and reconstituted in 5 ml methanol before fluormetric analysis. The aquatic
phases were centrifuged for 12 min at 110xg (Beckman Microfuge 11). The resulting
supernatants were transferred into fresh tubes, and spun. The supernatants from the
second spin were used for fluorescent assay. Rho-123 concentrations were measured on a
fluorescent spectrophotometer described as below except that the standard curve was
prepared by diluting stock Rho-123 solutions (2 mg/100ml) with methanol.
Membrane Fluidity
Hepatic Membrane Vesicle Preparations
In order to determine LAS influence on membrane fluidity, hepatic membrane
vesicles were prepared and subjected to fluorescent anisotropy measurements according
to the method from Kleinow et al. 2006. Hepatic tissues (2 g) were homogenized in 10
volumes of ice-cold buffer A (12 mM Tris, pH 7.4, 300 mM Mannitol, 5 mM EGTA) and
centrifuged at 12,000g for 5 min at 4 °C (Rotor type JA 25.50, Beckman). The pellet was
discarded while the supernatant was spun at 48,000g for 15 min at 4 °C (Rotor type Ti
70, Beckman). The second pellet was resuspended in buffer and centrifuged again under
the same conditions. The pellet from the third spin was suspended in 500 µl of storage
buffer (50 mM Tris-HEPES, pH 7.5, 0.1 mM MgSO4, 200 mM KCl, 125 mM DMannitol, 5 mM EGTA), which were aliquoted, snap frozen in liquid nitrogen and stored
at −80 °C until fluorescence anisotropy analysis. Hepatic membrane protein content was
analyzed using folin phenol reagent with bovine serum albumin as a standard (Lowry et
al., 1951).
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Membrane Fluidity Measurements
Fluidities of hepatic plasma membranes were detected by measuring fluorescence
anisotropy (inverse of membrane fluidity) with the fluorescent probe, 1, 6-diphenyl-1,3,5hexatriene (DPH, Molecular Probes, Eugene, OR) at the corresponding temperature
(Houpe et al., 1996). Fluorescence polarizations studies were carried out at λEX = 362 nm,
λEM = 428 nm and slit width = 2 mm, using a spectrofluorometer (model FL3-22TAU3,
Spex Fluorolog-3, Jobin Yvon-Spex, Edison, NJ) equipped with automated polarization
accessory and two temperature regulated cell holders. Samples of hepatic membrane
vesicles, containing 150 μg protein in 50 μl storage buffer, were incubated with 8 μM
DPH in a total volume of 3 ml incubation buffer (10 mM HEPES-Tris, pH 7.5, 200 mM
KCl) for 30 min on ice. After transferred into a cuvette, the sample was allowed to
equilibrate for 10-15 min in the cell holders set to liver perfusion temperature. The
fluorescence anisotropy (r) values were calculated according to the following equation:
r = [Ivv−(Ivh×G)]/[Ivv+(2×Ivh×G)]
where Ivv and Ivh are the fluorescence intensities detected with vertical and horizontal
polarization of emission, respectively, when the excitation polarization is set in the
vertical orientation (Houpe et al., 1996). G factors, ratios of spectrophotometer sensitivity
for horizontal and vertical polarized light, were calculated as Ihv/Ihh where Ihv and Ihh are
the fluorescence intensities detected with vertical and horizontal polarization of emission
when the excitation polarization is set in the horizontal orientation (Lakowicz et al.,
1979).
Effects of LAS on In Vivo Accumulation of 3H-IVM and 3H-BaP
In these experiments, fish were individually housed in 15 L tanks supplied with a
constant water flow of 80 ml per min. A peristaltic pump continuously transferred a
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stable volume of the freshly prepared LAS solution into a mixed head tank supplied with
a constant water flow, in which it was diluted to the appropriate final concentrations.
LAS concentrations of test water were determined according to the published methods
(Abbott 1962). Concentrated stock solutions (1000 mg/l) of C18 LAS were prepared
every third day.
To evaluate the effect of environmental relevant concentrations of LAS on the
bioaccumulation of the pharmaceutical drug IVM and the pro-carcinogen BaP, six groups
of fish (n=3 or 4, 701.1 ±135.4g) were exposed to LAS for 12 days at either 0, 100, or
300 µg/l water. Starting on the 7th day of LAS exposure, catfish were administered 6
daily doses of 3H-IVM (10 µg/day/kg body weight) or 3H-BaP (40 µg/day/kg body
weight) by indwelling gavage tube in a slurry of semi synthetic diet.
In order to facilitate multiple gavage administrations of 3H-IVM or 3H-BaP, fish
were outfitted in dwelling stomach tubes 24 h prior to the six-day gavage administration.
Following anesthetization, fish was weighed and placed with a dorsal recumbent position
on operating table. The stomach tube was implanted and anchored to the cartilage
rostrum of the nares (Kleinow, 1991). The experimental diet slurry was produced by
mixing finely ground semi-synthetic diet with water (1:3). The appropriate amounts of
3

H-IVM (0.16 µCi/µg or 354.2 dpm/ng) in methanol or 3H-BaP (0.095 µCi/µg or 213.5

dpm/ng) in toluene were then evenly dispersed over the slurry diet, which were
thoroughly blended, evaporated under nitrogen and stored at −4°C until gavage
administration. In addition, BaP diet was shielded from light and stored under nitrogen.
Following six-day gavage administration, catfish were fasted for 24 h and
euthanized with MS-222 (250 mg/l). Blood samples (~ 2 ml) were first collected from the
caudal vein. Bile, gonads, abdominal lipids, liver, spleen, kidney, stomach, intestine,
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muscle, gill and brain were then harvested and weighed for total mass balance and aliqots
radioassayed for 3H-IVM or3H-BaP in the animals. In a similar fashion and purpose,
intestines were cut open, inverted, contents rinsed out with 0.9% saline; blotted and dried
before sample collected and analyzed. The volume of blood in fish was assumed to be 5%
of total body weight while the mass of the muscle tissue was regarded as carcass in the
mass balance determinations.
Fluorescent Assay
Fluorescence of Rho-123 in bile and perfusate samples from isolated perfused
livers was measured at excitation and emission settings of 507 and 529 nm wavelengths,
respectively,

and

20

nm

slit

width,

using

a

Hitachi

F-2000

Fluorescent

Spectrophotometer. Bile samples (20 µl) or those less than 20 µl added zero time-point
bile up to a volume of 20 µl, were diluted with teleost Ringer’s solution to a final volume
of 600 µl. Each perfusate sample (20 µl) was combined with zero time bile (20 µl) and
teleost Ringer’s solution to a final volume of 600 µl. Concentrations of Rho-123 was
calculated in dilutions by interpolation upon a standard curve of Rho-123 concentrations
formulated for each fish, using their individual zero time bile to minimize effects of
different bile salt concentrations and compositions on fluorescence background. If a
sample had reading outside of the standard curve range, it was diluted again up to a final
volume of 600 µl, using teleost Ringer’s solution mixed with zero time bile (30:1, v/v).
Radioassay
Tissues samples (~ 100 mg) and blood aliquots (100 µl) were digested at 50°C in
0.5 ml of tissue solubilizer TS-2 (Research Products International Corp., Mount Prospect,
IL) for 24 h. Following cooling, the samples were neutralized with glacial acetic acid (18
µL) and added to 4.5 ml of scintillant (Ultima Gold, Packard, Downers Grove, IL). Bile
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samples (100 µl) were not digested prior to adding 4.5 ml of scintillant. All scintillation
samples were dark adapted overnight before counting for 30min each with a Tri-Carb
Liquid Scintillation Analyzers (Model 1900 TR). Quench correction counting efficiency
and background were performed for all samples.
Methylene Blue Active Substances Analysis for Measurement of Concentrations of
LAS
Concentrations of anionic surfactant LAS in the water were determined by the
methylene blue technique (Abbott, 1962). 100 ml of water sample freshly collected were
treated with alkalified methylene blue solutions. The anionic surfactant LAS reacts with
the methylene blue active substance to form a chloroform soluble complex. The complex
is extracted and dissolved in the chloroform phase by rapidly shaking the separating
funnel for 1 min. The chloroform extract then passes through an acidified methylene blue
solution to wash out inorganic anions associated with methylene blue substances, which
have a low solubility in chloroform phase. The final chloroform extracts were measured
by a spectrophotometer (U-2000, Hitachi) at a wavelength of 650 nm. Quantification was
based on a four-point standard curve which was established from the results by treating
100 ml of water samples containing suitable amounts of LAS (0, 10, 20 and 40 µg).
Statistical Analysis
All data were processed and graphed with Microsoft Excel 2003 (Redmond, WA).
Data analysis was performed with the statistical software SigmaStat for Windows
(Version 1.0, Jandal Corporation, San Rafael, CA). One-way ANOVA was employed to
examine for significant differences at P < 0.05.
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RESULTS
Effects of LAS on Biliary Excretion of Rho-123
To investigate the effect of LAS on transport activity of Pgp, accumulation of the
prototypic Pgp substrate, Rho-123, in bile was examined, using in situ prepared, isolated
perfused livers. As seen in Figure 3.1, the addition of LAS (1, 5, 20 µM) decreased
movement of Rho-123 into bile in a concentration-dependent fashion. During the 210min liver perfusions the cumulative amounts of Rho-123 (nM/kg body weight) in bile
were significantly decreased by 18.6 (12.35 ± 1.91), 38.1 (9.39 ± 1.40) and 66.7% (5.06 ±
1.79) with increasing LAS concentrations at 1, 5 and 20 µM, respectively (p < 0.05).
The effect of acute temperature change on biliary accumulation of Rho-123 was
also evaluated. Temperature treatments of 23 oC and 28 oC as compared to controls (18
o

C) resulted in dramatic decreases in biliary excretion of Rho-123 by 90.4 (1.46 ± 0.41)

and 93.7% (0.97 ± 0.45), respectively, during the 210-min perfusions (p < 0.0001).
Effects of LAS on Hepatobiliary Disposition of Rho-123
The distribution of Rho-123 in liver as parent and metabolites, bile and perfusing
media, is shown with increasing LAS concentrations (Table 3.1). LAS at 1, 5 and 20 µM
resulted in significant increases of Rho-123 retained in liver by 14.4 (65.39 ± 3.55 µg),
20.0 (68.63 ± 3.67 µg) and 25.7% (71.85 ± 3.98 µg), respectively, as compared with
control (57.16 ± 6.34 µg) (p < 0.05). This increased hepatic Rho-123 retention was
exhibited primarily as significant increases in the organic parent fraction. In contrast,
metabolites as aqueous Rho-123 in the liver was significantly decreased by LAS
treatments at 1 and 20 µM, suggesting decreased metabolism of Rho-123 in the liver
(Table 3.1). The increase in hepatic Rho-123 content was accompanied by decreased
movement of Rho-123 into bile for each of the LAS treatments (Table 3.1). Acute
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in Bile (nM/kg body weight)

18
15

*

12

*

9

*

6
3
0
CTR

1 μM

5 μM

20 μM

LAS Treatment Concentration

*

*

23 oC

28 oC

Temperature

Figure 3.1 - Excretion of Rho-123 into bile from isolated perfused catfish livers
exposed 210 min to 1 µM Rho-123 with vehicle control or LAS (1 µM, 5 µM or 20
µM) at 18 oC, or vehicle alone treated at 23 oC or 28 oC. Each column represents
mean ± SD (nM Rho-123 /kg body weight) (n = 5). * = Significantly different from
controls at p < 0.05.
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Table 3.1 - Effects of LAS on hepatobiliary disposition of Rho-123 at the end of 210min isolated liver perfusion of 1 μM Rho-123, coupled with vehicle or LAS at 1, 5 or 20
μM at 18˚C, or with temperature treatments at 23˚C or 28˚C, respectively.
Bile Excretion

Liver Extraction

Media

Total

Total
μg/210 min

Aqueous
Organic
μg/whole liver weight

Total
μg/250 ml

μg

Control

14.31 ± 2.33

0.79 ± 0.29

57.16 ± 6.34

6.30 ± 1.58

78.56 ± 7.82

1 μM LAS

*7.99 ± 1.45

* 0.34 ± 0.08

*65.39 ± 3.55

8.22 ± 1.14

81.94 ± 2.41

5 μM LAS

*7.30 ± 2.22

0.57 ± 0.23

*68.63 ± 3.67

5.26 ± 0.37

81.75 ± 4.53

20 μM LAS

*3.93 ± 0.66

* 0.39 ± 0.12

*71.85 ± 3.98

5.59 ± 1.35

81.75 ± 2.82

Temp 23˚C

*0.95 ± 0.24

* 0.31 ± 0.05

*67.54 ± 4.93

*11.82 ± 1.64

80.63 ± 5.99

Temp 28˚C

*0.67 ± 0.33

* 0.37 ± 0.18

*69.94 ± 3.94

*11.40 ± 1.35

82.38 ± 3.91

† Data represents mean ± SD. of three or four measurements.
*=Significantly different from controls (p<0.05).
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temperature increases of 5 and 10 oC (23oC and 28oC) resulted in increased retention of
Rho-123 in the whole liver by 18.2 (67.54 ± 4.93 µg) and 22.4% (69.94 ± 3.94 µg),
respectively. These increases in hepatic Rho-123 retention were a result of significant
increases of parent Rho-123 content (as detected in the organic fraction) and significant
decreases in metabolites (the aqueous fraction) as compared to the control (p < 0.05). In
addition, acute temperature treatments dramatically decreased Rho-123 equivalents found
in bile and significantly increased Rho-123 retained in the media by 87.6 (11.82 ± 1.64
µg) and 81.0% (11.40 ± 1.35 µg), as compared with the control (6.30 ± 1.58 µg) (p <
0.01) (Table 3.1).
Effects of LAS on Membrane Fluidity
In an effort to elucidate the mechanism by which LAS reduces Rho-123
movement into bile of the isolated liver perfusions, a DPH fluorescence polarization
study was performed. LAS treatments at 1, 5 and 20 µM resulted in significant decreases
of anisotropies (inverse of membrane fluidity) in the corresponding hepatic membranes
by 29.7 (0.102 ± 0.004), 32.4 (0.098 ± 0.005) and 38.6% (0.089 ± 0.003), respectively, as
compared with control (0.145 ± 0.005) (p < 0.001) (Fig. 3.2). The most prominent
decrease in anisotropy or increase in membrane fluidity was evident between control and
the 1 µM LAS treatment, while fluidity continued to increase with LAS concentration,
the changes were much smaller than the initial 1 µM treatment. Acute temperature
increases of 5 and 10 oC (23 oC and 28 oC) also resulted in significant decreases in
fluorescence anisotropy by 42.8 (0.083 ± 0.002) and 49.7% (0.073 ± 0.001), respectively
(Fig. 3.2). These findings suggest membrane fluidity was altered with LAS exposure and
acute increases in temperatures.
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Figure 3.2 - Anisotropy of hepatic membrane vesicles prepared from isolated
perfused livers, following exposure 210 min to 1 µM Rho-123 with vehicle control
or LAS (1 µM, 5 µM or 20 µM) at 18oC, or vehicle alone maintained at 23oC or
28oC. Each column represents mean ± SD (n = 5). * = Significantly different from
controls at p < 0.05.
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Influence of LAS on In Vivo Accumulation and Disposition of 3H-IVM
3

H-IVM molar equivalent concentrations were significantly increased in blood

and major individual organs including liver, kidneys, brain, gills, intestine, stomach,
muscle, and eggs, with increasing LAS treatments (Table 3.2). LAS treatments of 100
and 300 µg/l increased the dose remaining in fish at 24 hours after six daily consecutive
dosings by 39.0 and 77.9% for 3H-IVM, respectively (Fig. 3.3). When considering the
organ weight or volume, muscle, eggs and blood contributed the most to the composite
increase with the muscle contributing 24.8 and 53.0% of the observed increase for the
100 and 300 µg/l LAS dose, respectively. Concentrations of 3H-IVM equivalents
increased 1.6- and 2.2-fold in blood, 1.3- and 1.6-fold in liver, 1.5- and 2.2-fold in
kidney, 1.4- and 1.5-fold in intestine, 1.7- and 3.2-fold in brain, 1.4- and 1.8-fold in
muscle with LAS exposure at the 100 and 300 µg/l, respectively. As presented in Fig.
3.4, LAS treatments at 100 and 300 µg/l resulted in significant decreases of 26.7 and
51.0% in the ratios of bile/blood concentrations and 20.7 and 28.0% in the ratios of
liver/blood concentrations, respectively. The decreasing bile/blood ratios with either
LAS treatment were the result of significant increases in blood 3H-IVM in face of no
significant change in movement into bile (Table 3.2). The liver exhibited a modest
increase in 3H-IVM concentrations with LAS treatments. These 3H-IVM increases in the
liver were less than those observed for blood resulting in decreasing liver/blood
concentration ratios (Table 3.2).
Influence of LAS on In Vivo Accumulation and Disposition of 3H-BaP
LAS treatments lead to the increasing levels of 3H-BaP molar equivalents in
blood, bile and tissues such as liver, kidney, heart, eggs and stomach (Table 3.3). The
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Figure 3.3 - Tissue distribution of 3H-IVM equivalents as per cent of dose
following daily dietary administration of 3H-IVM at 10 µg/kg body weight to
catfish for six days starting on 7th day during a twelve-day exposure to water alone
(as control: CTR) or LAS at 100 or 300 µg/l. Each column represents mean ± SD
(n = 3 or 4). * = Significantly different from controls at p < 0.05.
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Figure 3.4 - Bile/blood and liver/blood 3H-IVM concentration ratios in catfish
following daily dietary administration of 3H-IVM at 10 µg/kg body weight to catfish
for six days starting on 7th day during a twelve-day treatment with water alone (as
control: CTR) or LAS at 100 or 300 µg/l. Each column represents mean ± SD (n = 3
or 4). * = Significantly different from controls at p < 0.05.
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Table 3.2 - Tissue concentrations of 3H-IVM equivalents following daily dietary
administrations of 3H-IVM at 10 µg/kg body weight to catfish for six days starting on
7th day during a twelve-day exposure to water alone (as control: CTR) or LAS at 100 or
300 µg/l water.
3

Tissues
Blood
Bile
Liver
Spleen
Kidney
Heart
Lipids
Brain
Gill
Intestine
Stomach
Muscle
Eggs

H-IVM Equivalent Concentrations (ng/g)
CTR

LAS 100 µg/L

10.72 ± 1.28
444.84 ± 59.51
52.74 ± 5.63
10.48 ± 2.92
28.46 ± 3.54
19.17 ± 6.12
54.17 ± 12.73
9.83 ± 1.17
15.91 ± 1.16
43.8 ± 4.80
25.84 ± 2.91
9.62 ± 0.84
18.13 ± 2.46

* 17.23 ± 1.44
459.29 ± 36.74
* 67.71 ± 2.59
13.43 ± 0.9
* 42.93 ± 3.04
20.82 ± 2.92
55.94 ± 13.01
* 17.10 ± 4.25
* 21.66 ± 1.54
* 61.87 ± 4.36
* 34.96 ± 3.39
* 13.68 ± 0.47
* 25.31 ± 1.24

LAS 300 µg/L
* 23.81 ± 3.45
491.81 ± 108.85
* 85.75 ± 13.97
* 22.26 ± 2.13
* 61.39 ± 8.91
* 35.56 ± 8.28
61.02 ± 20.07
* 31.29 ± 2.37
* 33.58 ± 6.25
* 66.41 ± 3.63
* 40.32 ± 7.49
* 17.61 ± 0.63
* 36.51 ± 2.91

† Values are expressed as ng 3H-IVM equivalents/g and data represents mean ± SD. of
three or four measurements.
* =Significantly different from controls (p<0.05).
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doses recovered from the whole fish at 24 hours after consecutive dosings were increased
by 50 and 157% with LAS exposure at 100 and 300 µg/l, respectively (Fig. 3.5). This
composite increase mostly came from contributions of intestine, muscle and liver. With
exposure to LAS at 100 and 300 µg/l, concentrations of 3H-BaP equivalents increased
1.6- and 3.8-fold in liver, 1.7- and 4.3-fold in kidney, 1.3- and 1.7-fold in intestine, 2.0and 3.9-fold in brain, 1.5- and 3.0-fold in muscle, 1.9- and 3.3-fold in eggs, respectively.
Bile concentrations increased significantly 1.7- to 1.9-fold for the 100 and 300 µg/l LAS
concentrations whereas liver concentrations increased 1.6- to 3.8-fold (Table 3.3). Blood
exhibited concurrent concentration increases (Table 3.3). Bile/blood concentration ratios
were significantly decreased by 39.2 % only with LAS exposure at 300 µg/l. No
significant change was noted for liver/blood 3H-BaP concentration ratios at either the 100
or 300 µg/l LAS concentration (Fig. 3.6).

DISCUSSION
Surfactants are among the most common contaminants found in domestic and
industrial wastewater and frequently occur with other contaminants as mixtures in the
aquatic environment (Lewis, 1992; Yang et al., 1998). As one of the most widely used
classes of surfactants, LAS has been found worldwide in a variety of aquatic
environments at different concentrations. LAS has been detected in sewage effluents and
in surface waters in the UK (1090 μg/l and 416 μg/l) (Holt et al., 1998; Fox et al., 2000)
as well as in the effluents of wastewater treatment plants in the USA (4 to 94 μg/l) (Trehy
et al., 1996). LAS has also been reported at concentrations of 20 to 1000 μg/l in outlets to
estuaries and near-shore marine waters in the North Sea (Berna et al., 1991; Stalmans et
al., 1991) and in Mississippi River water (0.1 to 2.8 μg/l) (Tabor and Barber, 1996).
Generally LAS levels in sediment have been reported to be much higher than in the water
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Figure 3.5 - Tissue distribution of 3H-BaP equivalents as per cent of total dose
following daily dietary administration of 3H-BaP at 40 µg/kg body weight to
catfish for six days starting on 7th day during a twelve-day exposure to water alone
(as control: CTR) or LAS at 100 or 300 µg/l. Each column represents mean ± SD
(n = 3 or 4). * = Significantly different from controls at p < 0.05.
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Figure 3.6 - Bile/blood and liver/blood 3H-BaP concentration ratios following daily
dietary administration of 3H-BaP at 40 µg/kg body weight to catfish for six days
starting on 7th day during a twelve-day exposure to water alone (as control: CTR) or
LAS at 100 or 300 µg/l. Each column represents mean ± SD (n = 3 or 4). * =
Significantly different from controls at p < 0.05.
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Table 3.3 - Tissue concentrations of 3H-BaP equivalents in catfish following daily
dietary administrations of 3H-BaP at 40 µg/kg body weight for six days starting on 7th
day during a twelve-day exposure to water alone (as control: CTR) or LAS at 100 or
300 µg/l.

3

H-BaP Equivalent Concentrations (ng/g)

Tissues
Blood
Bile
Liver
Spleen
Kidney
Heart
Lipids
Brain
Gill
Intestine
Stomach
Muscle
Eggs

CTR
8.44 ± 0.98
1040.41 ± 155.96
92.25 ± 4.33
7.94 ± 2.04
38.03 ± 2.01
8.58 ± 0.68
9.87 ± 2.53
5.10 ± 1.12
14.35 ± 1.79
965.60 ± 62.97
69.84 ± 33.06
2.66 ± 0.46
3.68 ± 0.44

LAS 100 µg/l

LAS 300 µg/l

* 14.75 ± 1.91
* 1779.63 ± 291.68
* 150.86 ± 10.92
11.98 ± 3.50
* 64.69 ± 14.88
* 16.10 ± 4.61
14.75 ± 3.10
* 10.02 ± 2.08
30.98 ± 11.22
1228.17 ± 186.37
* 203.28 ± 27.94
4.07 ± 1.08
* 7.11 ± 1.97

* 26.34 ± 1.33
* 1970.91 ± 147.24
* 349.68 ± 29.11
* 18.51 ± 1.66
* 162.71 ± 38.37
* 18.43 ± 1.55
* 61.48 ± 12.24
* 20.02 ± 4.81
* 36.04 ± 8.55
* 1667.35 ± 363.2
* 222.31 ± 73.98
* 8.05 ± 0.80
* 12.16 ± 0.29

† Values are expressed as ng 3H-BaP equivalents/g and data represents mean ± SD.
of three or four measurements.
* =Significantly different from controls (p<0.05).
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column due to limited degradation under anaerobic conditions (Ying, 2006). A range of
37 to 500,000 μg LAS /kg sediment (dry weight) have been reported (Bester et al., 2001;
International Program on Chemical Safety, 1996; Jensen, 1999).
Several early studies have suggested that surfactants enhance the bioavailability
and alter the disposition of other compounds in fish (Mann, 1962; Solon, et al., 1969; Pärt
et al., 1985). More up to date, investigations in the cancer treatment field have indicated
that surfactants have the potential to override the transporter mediated multidrug
resistance phenomenon exhibited by cancer cells (Orlowski et al., 1998; Bogman et al.,
2003; Regev et al., 1999; Drori et al., 1995; Hendrich and Michalak, 2003). The efflux
action of such transporters in the intestine is now known to be an important modulator of
bioavailability for a variety of orally administered drugs (Chan et al., 2004). In addition,
the excipient actions of surfactants have been shown to increase drug bioavailability from
the intestinal tract (Rege et al., 2002; Hugger et al., 2003). Collectively, these effects of
surfactants have been reported to occur as a result of specific transporter inhibition (Rege
et al., 2002; Orlowski et al., 1998; Bogman et al., 2003), membrane fluidization (Regev
et al., 1999; Hugger et al., 2003), compound solubilization (Strickley, 2004) and cellular
reentrance of effluxed compounds due to general increases in bidirectional membrane
permeability (Drori et al., 1995; Hendrich and Michalak, 2003). The current study
demonstrates that LAS inhibits the movement of Rho-123 into bile in the in situ prepared
isolated liver preparation and increases at environmentally relevant concentrations the in
vivo bioaccumulation of dietary 3H-IVM and 3H-BaP molar equivalents (parent and
metabolites) in catfish. These latter data suggest that LAS at low concentrations, for
which little overt toxicity is evident, may alter the exposure and bioaccumulation of other
potentially hazardous chemicals to which fish may be co-exposed. Such mixture
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interactions may augment exposure risk to not only the fish themselves, but also humans
consuming those contaminated fish that may have higher than expected body burdens.
LAS treatment resulted in a concentration-dependent inhibition of Rho-123
movement into bile of the in situ perfused liver (Fig. 3.1) and increased retention of Rho123 in liver tissues (Table 3.1). This increased compound retention in hepatic tissues was
associated primarily with increases in parent compound and a significant, but small
decline in formed metabolites. This latter finding is indicative of a limited, but
measurable interaction of LAS with some facet of the biotransformation process. The
nature of the interaction is unknown, but is likely to be associated with a membrane
linked enzymatic system such as Cytochrome P450. Other studies have shown the effects
of surfactants on biotransformation systems (Johnson et al., 2002; Batrakova et al., 2003
and 2004). Importantly, the increases in parent compound retention in the liver while not
stochiometrically related to the decrease in metabolites formed appeared to be primarily
related to total declines in compound content in the bile. Since the total amount of Rho123 used and observed in the perfusion media were similar for all liver perfusion
treatments, hepatic levels of Rho-123 increased with LAS treatment as would be
expected with characteristic surfactant properties, and bile Rho-123 amounts dropped
these results are most likely due to LAS effects upon permeability or transport function
within the hepatocyte-biliary vectorial pathway rather than the amount of Rho-123
accessing the hepatocytes from the perfusion media.
Membrane permeability and Pgp transport function are interdependent and for all
practical purposes inseparable. The functional vectorial transport of substrates by Pgp has
been clearly shown to be dependent on the passive permeability of the membrane to the
transported substrate (Eytan et al., 1996 and 1997). Compounds considered to be non120

transported modulators of Pgp activity have shown greater permeability and inward
diffusability (Scala et al., 1997; Mülder et al., 1995). For these compounds, if transported
by Pgp, movement is unrecognizable due to the membrane’s inability to maintain the
gradient and prevent compound back-diffusion (Barnes et al., 1996; Fert’e, 2000). Under
normal physiological conditions, Rho-123, a cationic Pgp substrate, demonstrates
restricted membrane movement and vectorial transport (Yumoto et al., 2001; Speelmans
et al., 1994; Heywang et al., 1998; James et al., 1977). The decrease in Rho-123
movement into bile with LAS exposure may due to altered membrane permeability
resulting from LAS-membrane interactions, by direct inhibition of Pgp transport or via
alteration of the membrane environment around Pgp, therefore influencing transporter
function. One of these alternatives or a combination at the apical hepatocyte bile interface
may result in increasing accumulation of Rho-123 in liver and decreased biliary
excretion.
Surfactants, as amphipathetic molecules, whose structures imitate that of
glycerophospholipids, are able to insert themselves between lipophilic tails of membrane
bilayers, resulting in disorder of the lipid-packing arrangement of membranes (Fert’e,
2000). The net result is the membrane becomes fluidized, facilitating the passive
diffusion of compounds (Lo, 2003), and increasing permeability (Drori et al., 1995;
Hendrich and Michalak, 2003). In the present Rho-123 perfusion experiment, LAS
exposure resulted in increased hepatic membrane fluidity. The fluorescence anisotropy
measurements demonstrated a 29.7% decrease at the 1 µM LAS concentration and
modest additional changes in membrane fluidity (inversely related to anisotropy) for the
higher 5 and 20 µM LAS concentrations (Fig. 3.2). These changes in membrane fluidity
with the 1 mM LAS treatment are likely to contribute to the increases in Rho-123
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permeability. Membrane fluidity changes, especially with the higher LAS concentrations,
were not stoichiometrically consistent with the concentration-dependent effects on Rho123 amounts transferred to the bile. The inconsistency here may be due to significant
LAS dose dependent changes in Rho-123 permeability occurring over a small range of
altered membrane fluidities once a critical point in gel /liquid phase transitions have been
attained (Block et al., 1976). Currently, there is little evidence in the literature to support
this concept. A second possibility is that the dose dependent decrease in Rho-123
movement into bile with LAS is not merely the result of changes in membrane
permeability as associated with increases in fluidity. From this perspective it is likely that
Pgp as the efflux transporter of Rho-123 may be at least partially inhibited by LAS. It has
been postulated that Pgp-interacting compounds exhibit characteristic surface-active
properties such as the capability to partition into a membrane and modify the surface
tension (Schinkel et al., 1996; Seelig, 1998). Clearly surfactants have these abilities. In
fact a number of studies have suggested that amphipathic surfactants including Tween 80,
Triton X-100 and Solutol HS-15 may be substrates or modulators of Pgp (Coon et al.,
1991; Zordan-Nudo et al., 1993). A likely conclusion for the present study is that LAS is
competing

with

Rho-123

for

transport.

Although

an

attractive

explanation,

characterization of similar interactions for other classes of better-studied amphipathic
lipophilic Pgp substrates and modulators have shown an array of relations including
competitive, noncompetitive and mixed interactions. This mixed profile provides a great
deal of uncertainty regarding their connection via a common transport site (Ayesh et al.,
1996). To add to the uncertainty both substrates and modulators stimulate Pgp ATP
utilization and displace photoligand binding on Pgp (Dayan et al., 1997; Beck and Qian,
1992; Liu and Sharom, 1996). A commonly cited hypothesis for these disparate results
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suggests that Pgp has multiple sites, some independent of others, for compounds to
interact with Pgp along its hydrophobic transmembrane domain (Ayesh et al., 1996; Boer
et al., 1996). The actual mechanisms and interrelationships have yet to be defined.
In the present study, acute temperature changes were used as a LAS free means
for membrane fluidization (Kleinow et al., 2006) and as a comparison for the effect of
LAS induced fluidity on transport of Rho-123 into bile. Acute increases of the perfusion
media and isolated liver preparation temperature [5 and 10 oC (actual temperatures of 23
o

C and 28oC respectively)] resulted in 42.8 and 49.7% decreases in fluorescence

anisotropy (increases in fluidity) (Fig. 3.2). This increase in fluidity almost completely
abolished transfer of Rho-123 into bile (Fig. 3.1). One interesting observation is that the
temperature increases resulted in hepatic Rho-123 levels in the same range as the LAS
treatments, however, caused 5.9-11.9 fold lower Rho-123 levels in the bile. These results
suggest that the hepatocyte to bile component of the pathway is preferentially affected
and that greater fluidity may produce further declines in Rho-123 transport into the bile.
Such findings are consistent with previous studies, which have found that acute
incremental elevations in temperature increased membrane fluidity (Robertson and Hazel
et al., 1999) along with intestinal membrane Rho-123 permeability and movement
(Kleinow et al., 2006).
It is useful to recognize that the anisotropy and hence fluidity measurements as
reported here are composite readings associated with the whole isolated hepatocyte
plasma membrane. As with other species, differences in membrane composition and
fluidity exist for regional domains of the plasma membrane (Schachter and Shinitzky,
1977) and with different cell types (Shinitzky and Inbar, 1976; Schulthess and Hauser,
1995; Crockett and Hazel, 1995). Specific domains, which are more influential in
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regionalized Rho-123 movement are possible. Larger changes in membrane fluidity for
specific domains with surfactants have been reported for fish (Zehmer and Hazel, 2003).
Regardless of the mechanism of interaction it is of interest to note that even with
the declines in bile levels of Rho-123 with LAS treatment, the bile concentrations when
normalized on a volume to a weight basis with the liver and media, were much higher
than both the liver and Rho-123 perfusion media concentrations suggesting that an active
process was still operative (Table 3.1). Together with the thermal results these studies
indicate that LAS and possibly other surfactants have the potential for greater fluidity
effects on transport and highlight a potential synergy with acute temperature change.
In the current study, LAS treatment increased the organ retention of all three
compounds examined. For Rho-123 this was evaluated only in the liver while for the in
vivo 3H-BaP and 3H-IVM experiments this finding was evident for all organs in the mass
balance assessments. The increases in the compound concentration followed a dose
response relationship with LAS exposure. This effect was generally greater for 3H-BaP
than 3H-IVM or Rho-123 at comparable LAS concentrations. In the liver, increases in
molar equivalent residues with LAS treatment over controls represented approximately
14.4% for Rho-123, 18.1-20.0% (Concentration: 28.4-62.6%) for 3H-IVM and 71.6321.0% (concentration: 63.5-279.1%) for 3H-BaP. A similar phenomenon was observed
for other organs in the in vivo studies for 3H-IVM and 3H-BaP. LAS increased 3H-IVM
and 3H-BaP whole body molar equivalents 39.0% and 77.9% and 50 and 157%,
respectively, for the 100 and 300 μg/l exposures. After considering organ weight and
fluid volumes, muscle, eggs, and blood contributed disproportionably more to retention
of 3H-IVM equivalents. For 3H-BaP equivalents, similar findings were evident for the
intestine, muscle, and liver. These single point mass balance studies suggest that LAS
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exposure at environmentally relevant concentrations result in altered residue amounts due
to changes in disposition ultimately affecting toxicokinetics. What is particularly
significant to note is that this effect was evident for all of these compounds of varying
chemical characteristics, but the effects were greatest for a lipophilic compound seldom
associated with Pgp transport.
Different allocation patterns for Rho-123, 3H-IVM and 3H-BaP equivalents
among the blood, liver and bile components of the hepatobiliary vectorial pathway
suggest that LAS interactions may differ qualitatively or quantitatively with different
compounds. LAS treatment decreased Rho-123 derived concentrations in bile, increased
Rho-123 levels in the liver and maintained concentrations in media at near constant
levels. Due to the chemical and transport characteristics of this compound these findings
are likely to be due to the effects of LAS on Pgp transport function and / or permeability
as described above. Increases in liver levels are likely to be related to reduction of Rho123 transport to the bile. On the contrary, upon LAS exposure, 3H-IVM molar
equivalents exhibited little change in bile levels and significant increases in both the
blood and liver 3H-IVM molar equivalent concentrations. The high bile to blood ratio of
3

H-IVM equivalents for the control is indicative of an active concentrating process. What

is of interest is that the bile to blood ratio declined with exposure to both the 100 and 300
LAS µg/l concentrations. This was a result of a very small increase in 3H-IVM
equivalents in the bile in face of significant increases in blood concentrations. A similar,
but less definitive finding (due to a moderate increase in liver IVM) was evident for liver
/ blood ratios. This suggests that LAS influences 3H-IVM movement at the apical
hepatocyte membrane and possibly the basal membrane. In addition, the significantly
elevated blood levels suggest that LAS increased intestinal bioavailability, possibly
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through excipient action or inhibition of Pgp in the intestine. LAS treatments lead to
increasing levels of 3H-BaP molar equivalents in blood and major organs including liver,
kidney, heart, eggs and stomach. A similar high bile to blood ratio was evident for both
controls and the 100 µg/l LAS exposure suggesting that an active secretion of 3H-BaP
equivalents into bile was evident. This could be contrasted with much lower liver/blood
ratios. Such results strongly suggest while some compound equivalent preference
occurred for the liver over blood it was much less pronounced than similar comparisons
for bile. These results suggest that the major active concentration process was likely to
occur on the apical canalicular interface. Although liver, bile and blood concentration
increased with the increased 300 µg/l LAS exposure concentration (Fig. 3.3) the relative
increase in bile concentrations were much smaller than the nearly proportional 3H-BaP
equivalent concentration increases in liver and blood for control, 100 µg/l LAS and 300
µg/l LAS exposures. The net result was a significant decline in the bile/blood ratio at 300
µg/l LAS. A number of features may be operative. The increases in 3H-BaP equivalents
for all components (bile, liver, blood) of the vectorial pathway at 100 µg/l LAS as well as
maintenance of bile/blood and bile/blood ratios as seen for controls suggest that the 100
µg/l LAS exposure increased intestinal bioavailability, or the total 3H-BaP equivalent
amount in the pathway. At the 300 µg/l LAS concentration, the bile concentration
increases modestly (89.4%) in comparison to blood (212.1%) and liver (279.1%). The net
result is a significant decline in bile/blood ratios. What may cause this is unknown, but it
is likely the higher LAS exposure not only facilitated greater intestinal permeability, but
also curtailed effective biliary transport. The latter may be evident through direct
transporter inhibition or an increase in apical permeability allowing compounds to back
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diffuse to the hepatocyte. Both processes result in accumulation of 3H-BaP equivalents in
liver, other organs and blood.
At the intestine greater compound solubility, greater mucosal permeability or
inhibition of retrograde ABC transporter efflux action, all potential mechanisms of the
surfactant LAS, would contribute to greater xenobiotic availability following a downhill
gradient from the intestinal lumen to the blood. On the elimination side enhanced
permeability of the bile canniculi or proximal tubular membrane or inhibition of efflux
transport action to the bile or urine would have the opposite effect. Less compound
equivalents would be available for elimination as transporter inhibition would reduce the
compound concentrating effect in bile or urine and increased permeability would
facilitate a down hill reentrance of compounds back into the tissues. The net result of
interactions at either one or both locations would be the same, accumulation of
xenobiotics or their metabolites in the fish. The significance of these effects is dependent
on a number of potential determinants including chemical characteristics, surfactant
interactions with the membranes or transporters as well as the operative concentration
gradients both at the intestine and elimination portals. The latter are likely to change with
exposure history and even with the course of the elimination and digestive processes. The
results presented for each Rho-123, 3H-IVM or 3H-BaP are consistent with varying levels
of interplay between the effects of LAS on membrane permeability and transporter action
at both the site of compound uptake (in vivo-intestinal bioavailability) and elimination.
Compound molecular weight, charge, lipid solubility and perhaps the transporter
involved in compound movement are likely compound specific features altering
permeability or transport. For Rho-123 studies that increased intestinal bioavailability
was not available for interaction because of the in situ experimental design. This
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precludes direct comparison with in vivo studies, but also isolates the effect of LAS
largely to the hepatocyte-bile vectorial pathway of elimination.
Since membranes are amphipathic with both polar interfacial areas and a
hydrophobic core, compounds transversing the plasma membrane or accessing Pgp in the
inner leaflet must partition in the polar interfacial region of the membrane bilayer,
partition and diffuse through the hydrophobic membrane core and desorb from the
opposite interfacial region of the membrane.

This process does not appear to be

determined solely by compound lipophicity, but appears to be influenced by other
compound-membrane interactions in the various regions of the membrane such as
electrostatic interactions, charge delocalization or screening, affinity for anionic lipids,
dielectric constant and surface potential of membrane interface (Speelmans et al., 1994;
James et al., 1977; Madden and Redelmeier, 1994; Webb et al., 1995; Mankhetkorn and
Garnier-Suillerot, 1998; Fernández and Fromherz, 1977; Flewelling and Hubbell, 1986).
Of the compounds examined, Rho-123 (mw: 469 g/mol), a moderately lipophilic cation,
and IVM (mw: 875 g/mol), a moderately lipophilic neutral compound, have been shown
to be substrates of Pgp (Yumoto et al., 2001; Schinkel et al., 1994). BaP (mw: 252
g/mol), a more lipophilic neutral compound, is readily metabolized to a variety of anionic
conjugates with characteristics consistent with Mrp substrates (Srivastava et al., 2002).
For Pgp substrates which are lipophlic cationic compounds, such as Rho-123, high
affinity for polar interfacial sites resulting from electrostatic interactions oppose
movement to the opposite membrane leaflet. However, once compounds are in the
lipophilic core the charge of the cation is delocalized or screened by lipophilic moieties
allowing movement through the core. This initial restriction on the passive permeation
process allows Rho-123 to be transported out of the cell of reducing accumulation. For
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weak lipophilic bases the protonated form has high affinity for anionic lipids and the
charge impedes diffusion. Neutral forms favored at lower pKa diffuses move rapidly.
Proportions of the charged and uncharged forms at the membrane surface depend on pH
and ionic compositions of aqueous phase and the dielectric constant and surface potential
of membrane interface. In contrast lipophlic anions such as BaP conjugates diffuse more
rapidly than similar featured cations, due to dipolar potential, have lower affinity for
membranes and accumulate independent of Pgp activity.
Compounds that exhibit some degree of lipophilicity and capability to cross
membranes also display energetically unfavorable interactions with water in the aquatic
environment. Water promotes partitioning of these types of compounds into organic
sediments and living organisms including primary producers and consumers at the
assorted trophic levels. Research has indicated that a primary means that these
contaminants enter fish is via dietary transfer and for certain contaminants
biomagnification along the aquatic food chain (Dietz et al., 2000). Factors that influence
the efficiency and the amount of contaminants passed through food include the type and
length of the food chain (Rasmussen et al., 1990; Broman et al., 1992; Cabana and
Rasmussen, 1994), existing body burdens (Doi et al., 2000; Barber et al., 1991), the
lipophilicity and size of the compound, exposure concentrations, bioavailability,
biotransformation (Ivanciuc et al., 2006) and physical features such as temperature
(Gewurtz et al., 2006). Fish represent a significant portal by which contaminants enter
into the human diet. On a global and per capita basis fish are consumed in increasingly
greater quantities (Hastein et al., 2006). As a high protein foodstuff consumption of fish
has been publicized as providing healthful effects in preventing cardiovascular disease
(Mori and Woodman, 2006; Breslow 2006), strokes (Bouzan et al., 2005), macular
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degeneration (Seddon et al., 2006), dementia (Huang et al., 2005) as well as a variety of
other disorders. For certain classes of contaminants such as organochlorines and
polyaromatic hydrocarbons, consumption of fish has been estimated to account for as
much as 65-90% of the existing human body burden (Fürst et al., 1992; Svensson et al.,
1995; Hattemer-Frey and Travis, 1991). Consistent with these findings correlations have
been made between consumption patterns of contaminated fish and health effects
including developmental and educational deficits in children (Mendola et al., 2005;
Vartiainen et al., 1998; Faroon et al., 2001).
Risk evaluation of chemicals in the environment must take in account the
compound’s toxicity, persistence and bioaccumulation. For many environmental
chemicals complete information is rare especially that regarding bioaccumulation in fish.
In 2004, the UN established a directive requiring that information regarding compound
bioaccumulation in fish must be available for each of the chemicals in production. The
goal of this process is to identify compounds, which pose undue risk because of their
bioaccumulation properties. Existing partitioning techniques using physicochemical
characteristics such as lipophilicity, have identified compounds with the potential to
bioaccumulate (Voutsas et al., 2002), however, these methods do not identify compounds
for which bioaccumulation is significantly reduced by biotransformation. Due to the
thousands of compounds yet unevaluated and the potential restrictions placed upon
targeted compounds, efforts are underway to develop in vitro and in silico techniques to
accurately and cost-effectively predict bioaccumulation in light of a compound’s
potential for biotransformation. Conversely, factors that enhance bioaccumulation have
not received much attention probably due to the complexity and unknown importance of
the issue.
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The abundant and widespread use of surfactants presents the opportunity for
potential interactions with the mechanisms of disposition and toxicity for a multitude of
other compounds in the environment. Degradation of surfactants discharged from
municipal or industrial sources, is dependent on the time maintained under aerobic
conditions (Kimerle et al., 1977; Kimerle, 1989; Karsa and Porter, 1995). This
degradation process is significantly reduced for shorter intervals and under anaerobic
conditions (Federle and Schwab, 1992; Prats-a et al., 2000). Anaerobic sediments often
act as repository for elevated surfactant concentrations and many other contaminants
(Westall et al., 1999; Federle and Schwab, 1992), support a variety of food chain
organisms and provide a food chain exposure route from the contained contaminant
mixture to the aforementioned organisms (Reynoldson, 1987; Casellato et al., 1992).
Surfactants also enter the environment by actions associated with remediation of
hazardous substances. Surfactants may be used in remediation of contaminated soils to
facilitate compound recovery (Burchfield et al., 1994, Baran et al., 1998) as well as for
aquatic based oil spills to disperse coalesced oil (Edwards et al., 2003; Harvey et al.,
1990). Such procedures can potentially bring significant amounts of surfactants, toxic
compounds and components of the aquatic and human food chain together (Lewis, 1992).
The current studies suggest that through alteration of permeability and transporter
function, LAS may enhance bioavailability, alter distribution and /or limit dispositional
processes so to increase bioaccumulation of mixture components. The possibility exists
that surfactants will not only increase the levels of contaminants in fish, but also by so
doing increase the subsequent exposure of humans.
In conclusion, these results suggest that LAS may influence the bioaccumulation
of xenobiotics from environmental mixtures. LAS at environmentally relevant exposure
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concentrations enhanced both oral bioavailability and decreased compound disposition
over the time frame and sampling regimes examined. At this time it is unknown if the
effects observed are representative, however, these results do occur for several
compounds with different characteristics. Responses were not confined to known Pgp
substrates. While these compounds all exhibit some degree of lipophilicity, it is uncertain
what compound properties promote or conceivably enhance the effects observed. Initial
indications suggest that variation in findings between compounds may result from
differing contributions of altered permeability and transporter function both at the site of
absorption and elimination. However, the general response elicited for all compounds
suggests that basic mechanisms, perhaps at the membrane may be involved. From the
animal perspective, it is also of interest that waterborne LAS exposure influences uptake
and disposition of dietary administered compounds. At the environmental level it is
unknown if such a response is more pronounced for certain organisms such as those
associated with the benthos or if the response will be seen or even magnified at each level
of the food chain. Full-scale bioaccumulation studies will be necessary to better evaluate
the effects of LAS on this process. These investigations will define the environmental
and toxicological relevancy of these mixture interactions.
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CHAPTER 4: SUMMARY AND CONCLUSIONS
Fish in impacted environments are exposed a great number of contaminants as
well as pharmaceutical agents as runoff from agriculture and used in aquaculture. The
extent of systemic toxicity and biochemical effects of these compounds to fish and the
fish consuming public is dependent on the uptake, bioavailability and bioaccumulation of
these chemicals in fish. Therefore, understanding factors that influence bioavailability
and bioaccumulation of these chemicals from the environment becomes essential in the
determination of the effects of these compounds to fish and human health. Membrane
permeability is a key determinant of absorption, distribution and elimination of chemicals
in the body (Ayrton and Morgan, 2001). Recently, studies in mammals suggest the active
membrane efflux mechanism of the ABC transporters P-glycoprotein (Pgp) and
multidrug resistance related protein (Mrp) may limit absorption and facilitate elimination
of drugs (Kurata et al ., 2002; Liu and Hu, 2000; Fromm, 2000). The studies presented
here investigated the effect of the environmental contaminants, dieldrin, a persistant
organochlorine pesticide, and linear alkylbenzene sulfonates (LAS), a surfactant, on Pgp
transport and membrane permeability as related to the retention of two pharmaceutical
drugs tetracycline and ivermectin (IVM) and the PAH and carcinogen benzo[a]pyrene
(BaP). These compounds were selected based on indications of possible involvement
with the mechanisms examined and environmental relevance.
Initial in situ experiments using isolated perfused liver preparations demonstrated
that the antibiotic drug tetracycline decreased movement of the Pgp prototypic substrate
Rhodamine-123 (Rho-123) into bile. This finding was consistent with tetracycline as a
substrate as well as a competitive inhibitor of Pgp transport. Further, verapamil, a Pgp
prototypic competitive inhibitor, resulted in a significant decrease in biliary excretion of
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3

H-tetracycline, providing further evidence that Pgp transport plays a role in the hepatic

disposition and bioavailability of tetracycline. Biliary excretion is a key pathway for
elimination of tetracycline from the body (Plakas et al., 1988). Finally, the marked
inhibitory effects of dieldrin on biliary excretion of Rho-123 and 3H-tetracycline were
demonstrated. Dieldrin at 20 µM inhibited 3H-tetracycline transport to a greater extent
than verapamil. These results suggested that dieldrin acted as a more potent inhibitor of
Pgp than verapamil.
In contrast to the inhibitory effects of dieldrin on transport of 3H-tetracycline into
bile in isolated perfused livers, a chronic low-dose pretreatment of dieldrin (0.1 mg/kg
body weight per day for 4 weeks) resulted in an increase in the plasma clearance as well
as a decrease in tissue distributions and AUC0- 96h for administration of a subsequent
single intra-aorta dose of 3H-tetracycline in catfish. These alterations were correlated
reasonably well with an increase of Pgp expression in the liver tissues in dieldrin
pretreated fish, which facilitated the clearance and elimination of 3H-tetracycline. These
findings indicated that Pgp induction here may well be the most important factor for these
alterations. Besides Pgp induction, induced metabolized enzymes may be involved to
alter disposition and pharmacokinetics of tetracycline in fish. However, previous studies
have shown that dieldrin-induced biotransformation enzymes were not observed in fish
(Vodicnik et al., 1981) and tetracycline has been shown to undergo minimal metabolism
in animals (Aronson, 1980). Therefore, these studies support the concept that Pgp
induction contributed to these alterations of the in vivo disposition and pharmacokinetics
of 3H-tetracycline.
Additional in situ studies examined the effect of the surfactant C18 LAS (1, 5,
and 20 µM), including environmentally relevant concentrations, on the hepatobiliary
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disposition of Rho-123 in isolated perfused livers. These studies demonstrated a
concentration-dependent inhibition of Rho-123 movement into bile and increased
retention of Rho-123 in liver tissues. The increased hepatic retention of Rho-123 was
associated primarily with an increase in parent compound and a small decline in formed
metabolites. The latter finding suggested that a limited, but measurable inhibition of
biotransformation may occur. The increases in the parent compound in liver tissues
appear to be related to the declines in compound content in bile. LAS treatment at the 1
µM concentration resulted in a 29.7% decrease in fluorescence anisotropy (increased
membrane fluidity) in the corresponding hepatic membranes, and modest additional
changes at higher LAS treatments, which were not stoichiometrically related to changes
in Rho-123 movement into bile. The inconsistency suggested that effects of LAS on Rho123 movement into bile are not merely the result of changes in membrane permeability as
associated with increases in fluidity. It is likely that Pgp may be at least partially inhibited
by LAS treatments.
Sequential in vivo studies demonstrated that LAS at environmentally relevant
concentrations (100 and 300 µg/L) resulted in elevated 3H-ivermectin (IVM) and 3Hbenzopyrene (BaP) molar equivalents remaining in catfish in a dose-response fashion.
Concentrations of 3H-IVM and 3H-BaP equivalents in blood and major organs following
dietary administration increased with increasing LAS concentrations in the water. After
considering organ weight and fluid volumes, muscle, eggs and blood contributed
disproportionably more to increased retention of 3H-IVM equivalents in catfish, while for
3

H-BaP equivalents, similar findings were evident for intestine, muscle and liver. In

addition, different allocation patterns for 3H-IVM and 3H-BaP equivalents among the
blood, liver and bile components of the hepatobiliary vectorial pathway were observed,
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suggesting that LAS interactions may differ qualitatively or quantitatively with different
compounds. These results were consistent with varying levels of interplay between the
effects of LAS on membrane permeability and transporter action at both sites of
compound uptake in intestine and elimination such as the bile. Compound molecular
weight, charge, lipid solubility and perhaps the transporter involved in compound
movement are likely compound specific features altering permeability or transport.
In summary, these studies have shown that ABC transporters and/or membrane
permeability play a critical role in disposition and bioaccumulation of xenobiotics in fish.
Environmental contaminants may influence bioaccumulation and bioavailability of other
compounds in environmental mixtures through different interactions with transporters
and/or the plasma membrane. At the high concentrations, dieldrin appears to be a potent
Pgp inhibitor, which decreased biliary elimination of Pgp substrates Rho-123 and 3Htetracycline. In contrast, inductive effects of Pgp predominated at the low dose of dieldrin
with chronic exposure, which led to increased plasma clearance and decreased tissue
distributions of

3

H-tetracycline.

Studies with surfactants suggest that LAS at

environmentally relevant concentrations altered membrane permeability and the efflux
activity of Pgp in the isolated perfused liver and enhanced the oral bioaccumulation and
curtailed compound elimination in catfish. These effects occurred for a variety of
compounds with different characteristics. The importance of these later studies is that
apparently innocuous compounds such as surfactants may enhance the bioaccumulation
of more hazardous environmental contaminants in fish and hence in the human diet.
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